bone disease (medical condition which affects the bone)

main subject (P921)

Q121961689	Celostní osteopatická léčba: založená na systému Body Adjustment podle Littlejohna a Wernhama
Q122016878	Diagnostika a léčba osteoporózy a dalších onemocnění skeletu
Q122006760	Fasciální osteopatie: základy a techniky
Q121996279	Kineziologické tejpování v osteopatii a manuální terapii
Q122123136	Kineziologické tejpování v osteopatii a manuální terapii
Q122018829	Nervový systém v osteopatii: periferní nervy, mozkomíšní pleny, vegetativní systém
Q122049232	Onemocnění skeletu u dětí: motolské pediatrické semináře 4
Q121962470	Osteopatie u epileptiků
Q121981648	Parietální osteopatie: základní přehled
Q122012745	Patomorfologie chorob kostí a kloubů
Q93529565	'Breaking the back' of Paget's bone disease
Q38829033	(18)F NaF PET/CT in the Assessment of Metastatic Bone Disease: Comparison with Specific PET Tracers
Q69413208	(Chloro-4 phenyl) thiomethylene biphosphonate in Paget's bone disease
Q68392072	1 in 4 Irish women suffer bone disease
Q66883312	1,25-Dihydroxycholecalciferol Deficiency: The Probable Cause of Hypocalcemia and Metabolic Bone Disease in Pseudohypoparathyroidism
Q71595487	1-Alpha-hydroxy vitamin D in dialysis bone disease: radiological changes after 6 and 12 months of treatment
Q67692819	1-alpha-Hydroxyvitamin D3 in the management of primary hyperparathyroidism with bone disease
Q107217115	18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment
Q76848578	2 NEW METHODS FOR THE STUDY OF OSTEOPOROSIS AND OTHER METABOLIC BONE DISEASE
Q45000464	2 cases of acute leukosis in children under the aspect of generalized bone disease
Q70337484	25-Hydroxyvitamin D3 treatment of bone disease in primary biliary cirrhosis
Q94094949	3152 The role of myostatin in diabetic bone disease
Q94129437	320. UK-HOPS (HIV Osteoporosis Prevention and Screening)-Gaps in the Care of HIV Patients with Bone Disease
Q102152912	3D Analysis of Cemento-Osseous Lesions
Q51829454	3D image analysis and artificial intelligence for bone disease classification.
Q97677661	68Ga-Prostate-Specific Membrane Antigen PET-Positive Paget Bone Disease With Metastatic Prostatic Carcinoma
Q43939094	99mTc(V)-DMSA scintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophy
Q40051081	99mTc-pyrophosphate in demonstrating bone disease of parathyroid dysfunction
Q93605150	A Colour Atlas of Bone Disease
Q93774760	A Colour Atlas of Bone Disease
Q94068223	A Colour Atlas of Bone Disease
Q62618688	A Cross-Sectional Study of Growth and Metabolic Bone Disease in a Pediatric Global Cohort Undergoing Chronic Hemodialysis
Q66892900	A Longitudinal Study of Bone Disease after Successful Renal Transplantation
Q28552810	A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease
Q57711823	A Patient With Autoimmune Liver Disease on Steroids: Screening and Treatment of Bone Disease
Q36417527	A Rare Case Report of Extensive Polyostotic Gorham's Disappearing Bone Disease Involving the Upper Extremity
Q72393008	A Role for the Intestine in the Bone Disease of Juvenile X-Linked Hypophosphatemic Mice: Malabsorption of Calcium and Reduced Skeletal Mineralization*
Q34587425	A STUDY OF THE SERUM PHOSPHATASE IN BONE DISEASE
Q107501003	A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
Q55055086	A Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants
Q105786932	A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method
Q99081597	A Trial to Evaluate Safety and Efficacy of Autologous CD34+ Cells With a Lentiviral Vector Encoding the TCIRG1 Gene
Q81814613	A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease
Q41907237	A case of autoinflammatory skin and bone disease flared by a change in osteoporosis management
Q78822846	A case of pachydermoperiostosis (Touraine's disease).
Q98215634	A case series of distal renal tubular acidosis, Southeast Asian ovalocytosis and metabolic bone disease
Q71357420	A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease
Q92003659	A contemporary therapeutic approach to bone disease in beta-thalassemia - a review
Q71541812	A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease
Q40350326	A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Q47874588	A dialogue on analogues Newer vitamin-D drugs for use in bone disease, psoriasis, and cancer
Q37401081	A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.
Q91380134	A hemodialysis patient with bone disease after pregnancy: a case report
Q43951865	A high prevalence of metabolic bone disease in exclusively breastfed very low birthweight infants in Dar-es-Salaam, Tanzania
Q52463043	A historic bone disease (in Erasmus of Rotterdam)
Q37671439	A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
Q35145071	A low incidence of parathyroid bone disease in chronic renal failure on maintenance haemodialysis
Q74462959	A method for examining the chemical basis for bone disease: synchrotron infrared microspectroscopy
Q36738580	A microradiographic study of bone disease in uremia
Q44445038	A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients
Q73456747	A multidisciplinary renal clinic for corticosteroid-induced bone disease
Q73457002	A murine model of inflammatory bone disease
Q40765325	A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients
Q40101765	A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer
Q87032346	A novel claudin-16 mutation, severe bone disease, and nephrocalcinosis
Q24297354	A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
Q39483693	A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma
Q91516862	A patent review of bisphosphonates in treating bone disease
Q59392918	A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease
Q50229125	A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
Q71573089	A possible role of vitamin D in the genesis of parenteral-nutrition-induced metabolic bone disease
Q90314937	A potential new target for autoinflammatory bone disease
Q67460055	A potential relationship between long-term fluoride exposure and incidence of metabolic bone disease in renal failure
Q53503721	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Q73469690	A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain
Q71665191	A rare genotypic bone disease: "pycnodysostosis" (a new case in a 60-year-old man)
Q58799397	A scoping review on the surgical management of metastatic bone disease of the extremities
Q58086625	A simple procedure for the rapid histologic diagnosis of metabolic bone disease
Q77152829	A structural approach to renal bone disease
Q74409689	A survey of bone disease
Q69993120	A survey of bone disease in the Alpk/AP rat
Q36380541	A systematic review of genetic skeletal disorders reported in Chinese biomedical journals between 1978 and 2012.
Q37185494	A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease
Q59035407	AB0779 Multidisciplinary Out-Patient Clinic (Reumatology-Endocrinology) for Patients with Complex Metabolic Bone Disease: 2 Years Experience
Q78410115	AN APPROACH TO THE DIAGNOSIS OF METABOLIC BONE DISEASE IN THE ELDERLY PATIENT
Q55428315	ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Q76961967	ATYPICAL MYCOBACTERIA AS A PROBABLE CAUSE OF CHRONIC BONE DISEASE: A REPORT OF TWO CASES
Q58086436	Absence of Metabolic Bone Disease in Adult Patients with the Nephrotic Syndrome and Normal Renal Function*
Q46090784	Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio
Q41622848	Absence of metabolic bone disease in the proximal femur in patients with fracture of the femoral neck.
Q34107067	Absent right iliac bone on Tc99m MDP bone scan in a patient with Gorham′s vanishing bone disease
Q80021119	Abstracts of the 6th International Meeting on Cancer Induced Bone Disease, December 10-14, 2006, San Antonio, Texas, USA
Q38515031	Acquired bone disease in small preterm infants--a potentially fatal disorder
Q40125651	Action of calcitonin on osteoclasts in Paget's bone disease during long term treatment (author's transl)
Q36641571	Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease
Q33740176	Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Q71716318	Acute lung damage after bilateral insertion of femoral intramedullary interlocking nails for metastatic bone disease
Q36377482	Adiponectin regulates bone marrow mesenchymal stem cell niche through a unique signal transduction pathway: an approach for treating bone disease in diabetes
Q57643732	Advanced Imaging of Multiple Myeloma Bone Disease
Q37771744	Advances in management of bone disease in breast cancer
Q37853737	Advances in the biology and treatment of bone disease in multiple myeloma
Q78769316	Advances in the biology and treatment of myeloma bone disease
Q53228114	Advances in the molecular pharmacology and therapeutics of bone disease and International Symposium on Paget's Disease July 10-14, 2007 St. Catherine's College, Oxford, UK.
Q73173235	Advances in the treatment of Paget's bone disease
Q33829022	Advances in the understanding of myeloma bone disease and tumour growth
Q67922461	Adynamic Bone Disease in Uremia: May It Be Idiopathic? Is It an Actual Disease?
Q43797476	Adynamic bone disease and malnutrition-inflammation-cachexia syndrome
Q40697137	Adynamic bone disease in patients with uremia.
Q39239811	Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.
Q57225919	Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis
Q54252452	Adynamic bone disease, anaemia, resistance to erythropoietin and iron-aluminium interaction.
Q87018960	Adynamic bone disease: a 14-year case report
Q36148772	Adynamic bone disease: an update and overview.
Q37474259	Adynamic bone disease: clinical and therapeutic implications.
Q34453297	Adynamic bone disease: from bone to vessels in chronic kidney disease
Q41571143	Adynamic bone disease: pathogenesis, diagnosis and clinical relevance
Q35121710	Aetiology of bone disease and the role of bisphosphonates in multiple myeloma
Q72027534	Alcohol and bone disease
Q72172131	Alcohol-induced bone disease in the absence of severe chronic liver damage
Q41113371	Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation
Q72837129	Alcohol-induced bone disease: relationship to age and parathyroid hormone levels
Q70473821	Alternate calcitonin and etidronate disodium therapy for Paget's bone disease
Q64123778	Alternative Treatments in Acute Mountain Sickness
Q34571176	Aluminium and bone disease in chronic renal failure
Q34072250	Aluminium bone disease in patients receiving plasma exchange with contaminated albumin
Q39261811	Aluminium-induced bone disease in uremic rats: effect of deferoxamine
Q69904796	Aluminium-related bone disease and haemodialysis
Q70598167	Aluminium-related bone disease presenting with calcaneal stress fractures
Q67740768	Aluminum and TPN-related bone disease
Q72716794	Aluminum and metabolic bone disease
Q68724056	Aluminum and renal bone disease in Australia
Q71648047	Aluminum as a factor in the bone disease of long-term parenteral nutrition
Q70468338	Aluminum associated bone disease: clinico-pathologic correlation
Q68974004	Aluminum bone disease in children: radiographic features from diagnosis to resolution
Q70022230	Aluminum bone disease in children: radiographic features from diagnosis to resolution
Q67919995	Aluminum load and histological bone disease in hemofiltration and hemodialysis
Q68841591	Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population
Q69091307	Aluminum-associated bone disease: considerations on the pathogenesis and the effects of deferoxamine treatment
Q44789880	Aluminum-associated bone disease: what's in a name?
Q69654370	Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis
Q68818407	Amniotic fluid osteocalcin concentrations in pregnancies uncomplicated by fetal bone disease
Q72151607	Amyloid bone disease and highly permeable synthetic membranes
Q50355728	An Address ON ACUTE BONE DISEASE IN CHILDREN: Read before a Meeting of the Isle of Thanet Division of the British Medical Association
Q97592911	An Early Myeloma Bone Disease Model in Skeletally Mature Mice as a Platform for Biomaterial Characterization of the Extracellular Matrix
Q70990710	An aspect of metabolic bone disease with idiopathic osteonecrosis of the femoral head
Q71132208	An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease
Q68895683	An investigation of vanishing bone disease
Q41125390	An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
Q40185368	An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma
Q58556408	An overview of the neurosurgical implications, pathophysiology, diagnosis and recent treatment strategies for Grade IV idiopathic osteolysis, also known as Gorham-Stout or phantom bone disease
Q41570205	An unusual case of disappearing bone disease in the mandible and literature review
Q41606373	An unusual presentation of metastatic bone disease in a subject with Paget's disease of bone
Q52039460	Analysis of renal bone disease treatment in dialysis patients.
Q38281138	Anemia and bone disease of chronic kidney disease: pathogenesis, diagnosis, and management.
Q67702051	Aneurysmal cyst of bone: disease or symptom
Q34180246	Angiomatosis of bone and soft tissue: a spectrum of disease from diffuse lymphangiomatosis to vanishing bone disease in young patients
Q37694746	Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells
Q24534971	Anticonvulsant drugs and bone disease in the elderly
Q70388317	Anticonvulsant drugs, folate deficiency, and metabolic bone disease
Q77848534	Anticonvulsant-induced bone disease
Q74519165	Anticonvulsant-induced bone disease: a plea for monitoring and treatment
Q89516735	Antidiabetic and antiosteoporotic pharmacotherapies for prevention and treatment of type 2 diabetes-induced bone disease: protocol for two network meta-analyses
Q34421862	Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients
Q71229949	Application of a continuous spectrophotometric assay for 5'nucleotidase activity in normal subjects and patients with liver and bone disease
Q36360754	Approach to the prostate cancer patient with bone disease
Q98396685	Appropriate Phosphorus Intake by Parenteral Nutrition Prevents Metabolic Bone Disease of Prematurity in Extremely Low Birth Weight Infants
Q89112834	Are Bone Disease and Cardiovascular Disease Risk Correlated in an HIV Cohort?
Q36029282	Are new vitamin D analogues in renal bone disease superior to calcitriol?
Q53387826	Are we trumping bone disease in prostate cancer?
Q44601622	Arrest of hyperparathyroid bone disease by the use of dihydrotachysterol in patients undergoing chronic hemodialysis
Q44200763	Arrest of hyperparathyroid bone disease with dihydrotachysterol in patients undergoing chronic hemodialysis
Q72013678	Aspects of renal bone disease
Q35645547	Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden.
Q36727138	Assessing response of myeloma bone disease with diffusion-weighted MRI.
Q47163664	Assessment and clinical management of bone disease in adults with eating disorders: a review.
Q93590475	Assessment and treatment of bone disease
Q67593029	Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level
Q72166092	Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease
Q26750574	Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions
Q67570221	Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients
Q39835438	Assessment of metabolic bone disease: review of new nuclear medicine procedures
Q53285767	Assessment of the impact of targeted therapy on metastatic bone disease in renal cancer.
Q72234300	Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
Q35141828	Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study
Q98293278	Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study
Q46650417	Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients
Q80165408	Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients
Q35069147	Association of mineral composition of neonatal intravenous feeding solutions and metabolic bone disease of prematurity
Q67566979	Asymmetric clubbing as a manifestation of sarcoid bone disease
Q37956225	Asymptomatic Paget's bone disease in ethnic Thais: a series of four case reports and a review of the literature
Q71140734	Atlas of computerized blood flow analysis in bone disease
Q72510795	Atraumatic posterior pelvic ring fractures simulating metastatic disease in patients with metabolic bone disease
Q79767467	Attitude of Physicians towards the Management of Bone Disease in Hemodialysis Patients: A Questionnaire Based Survey
Q41148823	Autologous bone marrow support and bone disease in metastatic breast cancer
Q71646217	Autologous bone marrow support and bone disease in metastatic breast cancer
Q48203582	Autologous cell-based therapy for treatment of large bone defects: from bench to bedside
Q35114954	Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3.
Q78756573	Awareness of the link between bone disease and calcium intake is associated with higher dietary calcium intake in women aged 50 years and older: results of the 1991 CSFII-DHKS. Continuing Survey of the Food Intake of Individuals. Diet and Health Kno
Q36966216	B vitamins, homocysteine, and bone disease: epidemiology and pathophysiology.
Q76848698	BILATERAL RENAL LITHIASIS WITH NEPHROCALCINOSIS WITHOUT BONE CHANGES CAUSED BY PARATHYROID ADENOMA
Q38898202	BONE DISEASE IN AFRICAN GREEN MONKEYS
Q76585716	BONE DISEASE IN CHRONIC RENAL FAILURE
Q38029253	Bariatric surgery and bone disease: from clinical perspective to molecular insights.
Q37418042	Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?
Q68693142	Basilar impression and Paget's bone disease, in 2 patients with cerebellar tonsil herniation
Q78015781	Bibliography of the current world literature. Metabolic bone disease
Q80067457	Bibliography. Current world literature. Metabolic bone disease
Q80364414	Bibliography. Current world literature. Metabolic bone disease
Q80386514	Bibliography. Current world literature. Metabolic bone disease
Q81413838	Bibliography. Current world literature. Metabolic bone disease
Q74052699	Bibliography. Current world literature. Metabolic bone disease
Q74508224	Bibliography. Current world literature. Metabolic bone disease
Q74529081	Bibliography. Current world literature. Metabolic bone disease
Q69768763	Bilateral fracture of the femoral neck complicating uremic bone disease prior to chronic hemodialysis
Q73676751	Biochemical Evidence of Metabolic Bone Disease in Women Following Roux-Y Gastric Bypass for Morbid Obesity
Q35221731	Biochemical and genetic analysis of ANK in arthritis and bone disease
Q46751438	Biochemical and imaging alterations of renal bone disease in newly detected predialysis and on maintenance dialysis patients
Q36679458	Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?
Q70391069	Biochemical assessment of acute and chronic treatment of Paget's bone disease with calcitonin and calcium with and without biphosphonate
Q70670325	Biochemical assessment of bone disease in multiple myeloma
Q73288597	Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis
Q50976460	Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis.
Q78077740	Biochemical markers in the management of patients with metastatic bone disease
Q57786564	Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients
Q79190989	Biochemical markers of bone turnover in diagnosis of myeloma bone disease
Q71808142	Biochemical markers of bone turnover in patients with metastatic bone disease
Q36656424	Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls
Q44082853	Biochemical measurements in the prediction of histologic subtype of renal transplant bone disease in women
Q68459712	Biochemistry and radiologic diagnosis of bone disease
Q55278740	Biodegradable Magnesium Alloys Developed as Bone Repair Materials: A Review.
Q98779880	Biomarkers of bone disease in persons with haemophilia
Q83214773	Biomedical research. Bone disease gene finally found
Q73482185	Biophysical studies on bone tissue. III. Osteopetrosis (marble bone disease)
Q38958627	Biopsy vs. peripheral computed tomography to assess bone disease in CKD patients on dialysis: differences and similarities.
Q99240906	Biotin supplement interference with immunoassays for parathyroid hormone and 25-hydroxyvitamin D in a patient with metabolic bone disease on maintenance hemodialysis
Q99579381	Bipolar Hemiarthroplasty and Parathyroidectomy at the Same Setting for Fragility Fractures Secondary to Renal Bone Disease
Q33600933	Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition
Q37203652	Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education
Q35283631	Bisphosphonate treatment of bone disease
Q43188067	Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series
Q36164448	Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity
Q104740640	Bisphosphonates and management of kidney stones and bone disease
Q37390429	Bisphosphonates and metabolic bone disease in the ICU.
Q41142697	Bisphosphonates and the treatment of bone disease in the elderly
Q36383420	Bisphosphonates for malignancy-related bone disease: current status, future developments
Q38586746	Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials
Q81429820	Bisphosphonates in metastatic bone disease: renal safety matters
Q33540268	Bisphosphonates in the treatment of malignant bone disease
Q24608900	Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis
Q84382824	Bisphosphonates: indications in bone diseases other than osteoporosis
Q90004940	Black Bone Disease of the Foot: A Two-Year Follow-Up Case Study
Q91565741	Black Bone Disease of the Skull
Q40813355	Black bone disease in a healing fracture
Q57644689	Black bone disease of the foot. Minocycline related pigmentation
Q38073374	Black bone disease of the foot: a case study and review of literature demonstrating a correlation of long-term minocycline therapy and bone hyperpigmentation
Q99347086	Bone Disease Associated With Hereditary Diffuse Leukoencephalopathy With Spheroids
Q39970839	Bone Disease after Kidney Transplantation
Q40091099	Bone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients
Q73767951	Bone Disease for the Rheumatologist: Osteoporosis, New Management Strategies, and Beyond. Symposium proceedings. Philadelphia, Pennsylvania, September 19-21, 1996
Q47393253	Bone Disease in Axial Spondyloarthritis.
Q38540406	Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient
Q90211105	Bone Disease in Mastocytosis
Q50888455	Bone Disease in Multiple Myeloma.
Q39051697	Bone Disease in Myeloma: The Claws of CRAB.
Q62615977	Bone Disease in Patients Awaiting Liver Transplantation. Has the Situation Improved in the Last Two Decades?
Q34597311	Bone Disease in Patients With Primary Sclerosing Cholangitis
Q90253332	Bone Disease in Patients with Ehlers-Danlos Syndromes
Q42910516	Bone Disease in Renal Transplantation and Pleotropic Effects of Vitamin D Therapy
Q38866904	Bone Disease in Thalassemia: A Molecular and Clinical Overview
Q50545111	Bone Disease in the Common Marmoset: Radiographic and Histological Findings.
Q55084686	Bone Disease in the Elderly: Disease Management in the Elderly, vol 3.
Q73563976	Bone Disease on the web
Q33555104	Bone Involvement in Rosai-Dorfman Disease (RDD): a Case Report and Systematic Literature Review
Q96643923	Bone Tumors: Metastatic Bone Disease
Q94387668	Bone and Bone Disease
Q36402724	Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases
Q68633288	Bone collagenase in assessment of the clinical course of metabolic bone disease
Q56936524	Bone disease & HIV
Q67271952	Bone disease after gastrectomy
Q70347635	Bone disease after gastrectomy
Q55281404	Bone disease after gastrectomy.
Q36704452	Bone disease after jejuno-ileal bypass for morbid obesity
Q39493399	Bone disease after jejuno-ileal bypass for obesity
Q66700594	Bone disease after jejunoileal bypass
Q35632536	Bone disease after kidney transplantation
Q82262855	Bone disease after kidney transplantation
Q94692938	Bone disease after kidney transplantation
Q34410041	Bone disease after liver transplantation
Q67966552	Bone disease after liver transplantation
Q73824000	Bone disease after liver transplantation
Q77106121	Bone disease after liver transplantation
Q42581112	Bone disease after liver transplantation should not be underestimated
Q43669070	Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics
Q68128457	Bone disease after orthotopic liver transplantation
Q35067392	Bone disease after renal transplantation
Q73219792	Bone disease after renal transplantation
Q73246891	Bone disease after renal transplantation
Q80138774	Bone disease after renal transplantation
Q80797217	Bone disease after renal transplantation
Q84912100	Bone disease after renal transplantation
Q36328951	Bone disease and HIV infection
Q83940983	Bone disease and HIV infection
Q39833638	Bone disease and aluminum: pathogenic considerations
Q45999218	Bone disease and bottle caps.
Q70083214	Bone disease and calcium absorption in primary biliary cirrhosis with special reference to vitamin-D therapy
Q39944294	Bone disease and chronic renal failure
Q37935735	Bone disease and cytokines in idiopathic hypercalciuria: a review
Q72848699	Bone disease and gluten sensitivity: time to act, to treat, and to prevent
Q37626599	Bone disease and hypercalciuria in children
Q67063586	Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3
Q36630973	Bone disease and idiopathic hypercalciuria
Q80619996	Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome
Q37805110	Bone disease and skeletal complications in patients with β thalassemia major
Q44251174	Bone disease and soft tissue calcification in chronic peritoneal dialysis
Q72553962	Bone disease and the removal of calcium fortification from flour
Q48339027	Bone disease as a new complication of hyponatremia: moving beyond brain injury
Q35892523	Bone disease associated with antiepileptic drugs
Q72435848	Bone disease associated with total parenteral nutrition
Q59012665	Bone disease cracks genetics
Q80521842	Bone disease drug discovery: examining the interactions between osteoblast and osteoclast
Q38109281	Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors.
Q91831296	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society
Q34139653	Bone disease from duodenal exclusion
Q37828253	Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.
Q46455866	Bone disease in African children with slipped capital femoral epiphysis: histomorphometry of iliac crest biopsies
Q38005253	Bone disease in CKD.
Q35593296	Bone disease in HIV infection
Q35019051	Bone disease in HIV infection: a practical review and recommendations for HIV care providers
Q35083081	Bone disease in HIV. What is the link?
Q39648947	Bone disease in Waldenstrom's macroglobulinemia: a possible indication for myeloma-type therapy
Q66898595	Bone disease in a dog similar to infantile cortical hyperostosis (Caffey's disease)
Q40701042	Bone disease in adolescents with acne fulminans and severe cystic acne: radiologic and scintigraphic findings
Q44552513	Bone disease in adult patients with β-thalassaemia major: a case-control study.
Q43444775	Bone disease in alcohol abuse
Q45948220	Bone disease in alcohol abuse.
Q70539380	Bone disease in analgesic nephropathy
Q27009000	Bone disease in anorexia nervosa
Q73696180	Bone disease in asthma
Q72999310	Bone disease in beta-thalassaemia
Q77787253	Bone disease in beta-thalassaemia major
Q93658948	Bone disease in biliary atresia: a not uncommon complication
Q51061171	Bone disease in burn patients.
Q51593894	Bone disease in calcium stone forming patients.
Q32065032	Bone disease in children and adolescents undergoing successful renal transplantation
Q40668113	Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
Q68714850	Bone disease in children with homozygous beta-thalassemia
Q40560142	Bone disease in cholestatic liver disease
Q69738651	Bone disease in chronic alcoholism: the value of plasma osteocalcin measurement
Q69735324	Bone disease in chronic childhood cholestasis. I. Vitamin D absorption and metabolism
Q68695176	Bone disease in chronic childhood cholestasis. II. Better absorption of 25-OH vitamin D than vitamin D in extrahepatic biliary atresia
Q84097919	Bone disease in chronic kidney disease: unraveling the details
Q45710763	Bone disease in chronic liver disease.
Q95300440	Bone disease in chronic pancreatitis
Q69388554	Bone disease in chronic renal failure
Q72205279	Bone disease in chronic renal failure
Q50064114	Bone disease in chronic renal failure and its modern therapy
Q78777107	Bone disease in chronic renal failure with particular reference to osteosclerosis
Q41677191	Bone disease in chronic renal failure--questionably the result of our "successful" treatment of uremia
Q54182435	Bone disease in chronic renal failure.
Q91656265	Bone disease in cirrhosis
Q38598049	Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.
Q37828291	Bone disease in cystic fibrosis: what's new?
Q37728029	Bone disease in diabetes
Q39331184	Bone disease in diabetes: another manifestation of microvascular disease?
Q37770798	Bone disease in elderly individuals with CKD.
Q70033593	Bone disease in end-stage renal failure
Q53964587	Bone disease in end-stage renal failure.
Q35817278	Bone disease in epilepsy
Q35939153	Bone disease in hemodialysis patients with particular reference to the effect of fluoride
Q68874787	Bone disease in hemodialysis patients with particular reference to the effect of fluoride
Q41755906	Bone disease in hypercalciuria: a new form of osteodystrophy?
Q38244174	Bone disease in hypoparathyroidism
Q36507240	Bone disease in idiopathic hypercalciuria
Q35151520	Bone disease in infants and children with hepatobiliary disease
Q81635897	Bone disease in infants with prolonged obstructive jaundice
Q39993962	Bone disease in intestinal malabsorption
Q37446206	Bone disease in kidney transplant patients
Q40915657	Bone disease in liver transplant recipients.
Q43484581	Bone disease in liver transplant recipients: incidence, timing, and risk factors
Q44445055	Bone disease in long-term adult kidney transplant patients with normal renal function
Q71865072	Bone disease in long-term dialysis
Q67755142	Bone disease in long-term haemodialysis: the association of radiological with histological abnormalities
Q64763372	Bone disease in long-term hemodialysis patients with low dialysate aluminium
Q53630253	Bone disease in long-term renal transplant recipients with severe osteopenia: a cross-sectional study.
Q70708010	Bone disease in maintenance hemodialysis. Clinical, biochemical and radiological correlates
Q33560526	Bone disease in medullary sponge kidney and effect of potassium citrate treatment
Q41360512	Bone disease in moderate renal failure: cause, nature and prevention
Q61852777	Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study
Q36737006	Bone disease in multiple myeloma
Q39903968	Bone disease in multiple myeloma
Q77787258	Bone disease in multiple myeloma
Q35422468	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management
Q68208279	Bone disease in multiple myeloma. A study of 237 cases
Q74398108	Bone disease in multiple myeloma: new markers, new treatments
Q34045789	Bone disease in multiple myeloma: pathophysiology and management.
Q34678320	Bone disease in myeloma
Q49819108	Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction.
Q80509875	Bone disease in nephrotic syndrome--prevention is better than cure
Q28543032	Bone disease in newly diagnosed lupus nephritis patients
Q38018212	Bone disease in organ transplant patients: pathogenesis and management
Q69788950	Bone disease in patients dialyzed with untreated water
Q52301481	Bone disease in patients on maintenance haemodialysis using softened or de-ionized water
Q41082686	Bone disease in patients receiving growth hormone.
Q91459192	Bone disease in patients with Gaucher disease
Q46538210	Bone disease in patients with chronic kidney disease under conservative management
Q53885798	Bone disease in patients with chronic renal failure and during long-term hemodialysis
Q41727895	Bone disease in patients with haemophilia A and B--where are we now?
Q45884578	Bone disease in patients with haemophilia. What is true?
Q38965528	Bone disease in patients with kidney disease: A tricky interplay
Q53956376	Bone disease in patients with long-term renal transplantation and normal renal function.
Q37874541	Bone disease in patients with primary biliary cirrhosis
Q37475818	Bone disease in patients with primary hypercalciuria and calcium nephrolithiasis
Q50636283	Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.
Q26864102	Bone disease in pediatric chronic kidney disease
Q37195350	Bone disease in pediatric idiopathic hypercalciuria
Q54520114	Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD
Q35624611	Bone disease in pediatric rheumatologic disorders
Q93831719	Bone disease in pet monkeys
Q38594397	Bone disease in post-transplant patients
Q38619075	Bone disease in post-transplant patients
Q71964275	Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH
Q81543106	Bone disease in preterm
Q38364729	Bone disease in preterm infants
Q80170447	Bone disease in primary biliary cirrhosis and renal tubular acidosis
Q72511247	Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?
Q72107442	Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D
Q71259493	Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia
Q50684179	Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.
Q38999541	Bone disease in primary biliary cirrhosis: lack of association with distal renal tubular acidosis
Q71129361	Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D
Q36209114	Bone disease in primary hypercalciuria
Q83770697	Bone disease in primary hypercalciuria
Q36280845	Bone disease in primary hyperparathyrodism
Q27010689	Bone disease in primary hyperparathyroidism
Q50099258	Bone disease in primary hyperparathyroidism
Q37934836	Bone disease in primary hyperparathyroidism.
Q70297216	Bone disease in prolonged parenteral nutrition: osteopenia without mineralization defect
Q43096541	Bone disease in prostate cancer.
Q70405354	Bone disease in renal failure. Clinical and histomorphometric studies
Q67887139	Bone disease in renal failure. Introduction
Q67386251	Bone disease in secondary hemochromatosis. Clinico-radiological study
Q44975665	Bone disease in secondary hyperparathyroidism
Q79758100	Bone disease in sickle cell anemia
Q95486287	Bone disease in systemic sclerosis: outcomes and associations
Q43050714	Bone disease in testicular and extragonadal germ cell tumours
Q37894557	Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects
Q33337925	Bone disease in thalassemia: a frequent and still unresolved problem
Q47366707	Bone disease in the Anglo-Saxons
Q35781009	Bone disease in the elderly
Q71041326	Bone disease in the elderly
Q64903554	Bone disease in the elderly.
Q37488052	Bone disease in the inflammatory bowel disease population.
Q26852787	Bone disease in the setting of HIV infection: update and review of the literature
Q27022238	Bone disease in thyrotoxicosis
Q72404026	Bone disease in thyrotoxicosis
Q69634922	Bone disease in two cases of cystinosis--histomorphometric analysis of the vitamin D effect
Q72836511	Bone disease in uraemia
Q39970075	Bone disease in uremia
Q69464045	Bone disease in uremia
Q71206715	Bone disease in uremia
Q35039812	Bone disease in uremic patients: advances in PTH suppression.
Q36082931	Bone disease in vitamin D-deficient patients with Crohn's disease
Q46635511	Bone disease in β thalassemia patients: past, present and future perspectives
Q69611847	Bone disease induced by anticonvulsant therapy and treatment with calcitriol (1,25-dihydroxyvitamin D3)
Q45921330	Bone disease induced by phenytoin therapy: clinical and experimental study.
Q53861898	Bone disease induced by radiation.
Q39679872	Bone disease metastatic to the jaws
Q36546146	Bone disease mimicking multiple myeloma in a octogenarian
Q66986233	Bone disease of chronic renal failure
Q36946234	Bone disease of prematurity
Q38743319	Bone disease of primary hyperoxaluria in infancy
Q71564574	Bone disease resulting from total parenteral nutrition
Q45714722	Bone disease with vitamin D receptor abnormality
Q45947423	Bone disease, gestational diabetes mellitus, and health care.
Q40806654	Bone disease, hypophosphatemia and hyperparathyroidism after renal transplantation
Q34729379	Bone disease: a primer/Part I. Clinical differences among vitamin D hormone compounds.
Q44813162	Bone echinococcosis. Apropos of 4 cases
Q36941678	Bone health in children and adolescents with perinatal HIV infection
Q68999921	Bone histologic response to deferoxamine in aluminum-related bone disease
Q67827652	Bone histology and clinical diagnostic criteria in aluminum-induced bone disease
Q41646669	Bone histology in metabolic bone disease: the diagnostic value of bone biopsy
Q35574216	Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy
Q81368239	Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease
Q74176156	Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity
Q34960867	Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions
Q80207823	Bone marrow edema: mild or nascent variant of ischemic bone disease
Q87492893	Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics
Q34038283	Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment
Q41878386	Bone odontoideum: about a case and review of the literature
Q34729265	Bone regeneration post-bone marrow necrosis mimicking hyperparathyroid bone disease
Q41148833	Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment.
Q36648116	Bone resorption predicts for skeletal complications in metastatic bone disease
Q92597577	Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response
Q67582786	Bone scanning in the diagnosis of infection bone disease (author's transl)
Q27021268	Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer
Q35592362	Bone-immune cell crosstalk: bone diseases.
Q46272139	Book Review: Photographic regional atlas of bone disease: a guide to pathologic and normal variation in the human skeleton
Q42737201	Boomerang Bone Disease: Bilateral Dysplasia of Ulna and Fibula
Q45966936	Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Q93029052	Brief Review on Metabolic Bone Disease
Q77212721	British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology
Q37809860	Burden of metastatic bone disease from genitourinary malignancies
Q90426684	Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer
Q37030106	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
Q51558211	Burn-associated bone disease in sheep: roles of immobilization and endogenous corticosteroids.
Q36813625	CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients
Q41172906	CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients: Assessor's comment.
Q91460766	CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3β/cyclinD1 signal pathway in Myeloma Bone Disease
Q84815127	CCR1 blockade and myeloma bone disease
Q36177928	CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Q88028536	CORR Insights®: Early Improvement in Pain and Functional Outcome but Not Quality of Life After Surgery for Metastatic Long Bone Disease
Q92149461	CORR Insights®: Thirty-day Postoperative Complications After Surgery for Metastatic Long Bone Disease Are Associated With Higher Mortality at 1 Year
Q37170908	CORR Insights®: complications of cemented long-stem hip arthroplasties in metastatic bone disease revisited
Q34292995	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease
Q41638087	Calcaneal abnormalities and erosive bone disease associated with sickle cell anemia
Q58086600	Calcifediol (25-Hydroxyvitamin D3) in the Treatment of Uremic Bone Disease
Q98238663	Calcification of Cardiac Valves in Metabolic Bone Disease: An Updated Review of Clinical Studies
Q93701504	Calcitonin and metabolic bone disease
Q70999278	Calcitonin secretion and bone disease severity in hypercalcaemic hyperparathyroidism
Q70504398	Calcitonin therapy for bone disease and hypercalcemia
Q50648822	Calcitriol for bone disease in patients with cirrhosis of the liver.
Q47120875	Calcitriol treatment in metabolic bone disease of prematurity with elevated parathyroid hormone: A preliminary study
Q44472061	Calcium absorption in bone disease associated with chronic cholestasis during childhood
Q39987473	Calcium and phosphorus metabolism and bone disease in uremia.
Q34421290	Calcium and vitamin D nutrition and bone disease of the elderly.
Q79508652	Calcium infusion in the detection of bone disease in parathyroid disorders
Q80597606	Calcium intake and metabolic bone disease after eight years of Roux-en-Y gastric bypass
Q85134397	Calcium metabolism in bone disease
Q55000209	Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol.
Q50935691	Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia.
Q71018580	Calcium-free hemodialysis is useful for evaluating parathyroid function and bone disease in chronic hemodialysis patients
Q36620343	Calcium-loading test and bone disease in patients with urolithiasis.
Q70228950	Calcium-oxalate-crystal-induced bone disease
Q38524098	Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease
Q68923203	Can a dietitian help prevent renal bone disease in the hemodialysis patient?
Q36910365	Can hyperparathyroid bone disease be arrested or reversed?
Q26997002	Can one evaluate bone disease in chronic kidney disease without a biopsy?
Q57176853	Can patient-specific finite element models better predict fractures in metastatic bone disease than experienced clinicians?: Towards computational modelling in daily clinical practice
Q53784664	Can renal bone disease be prevented?
Q56932977	Can the bone disease experienced by HIV-infected patients be attributed to HAART?
Q46184183	Can the combination of calcium and parathormone levels above K/DOQI guidelines be used as a marker of adynamic bone disease in African Americans?
Q68845439	Can the phospho-calcium analysis be simplified?
Q34091965	Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
Q66410989	Cancer Patient Perceptions of the Osteopathy Treatment: a Qualitative Study
Q30438185	Cancer treatment-related bone disease
Q30444698	Cancer-associated bone disease
Q61217357	Cancer-associated bone disease
Q28216025	Canine panosteitis: an idiopathic bone disease investigated in the light of a new hypothesis concerning pathogenesis. Part 1: Clinical and diagnostic aspects
Q68867235	Caring in the community for a family with a familial bone disease
Q26865580	Cartilage to bone transitions in health and disease
Q44047436	Carvedilol ameliorates low-turnover bone disease in non-obese type 2 diabetes.
Q88845285	Case Study: An intraoperative finding of black bone disease in a podiatric surgery patient
Q39810552	Case of Syphilitic Bone Disease
Q71992338	Case of marble bone disease with nasal discharge and obstruction as chief symptoms
Q53656725	Case report of a possible familial predisposition to metabolic bone disease in juvenile rhesus macaques
Q51736986	Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism.
Q80151188	Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy
Q37724780	Cathepsin L in metastatic bone disease: therapeutic implications
Q74001780	Causes and consequences of adynamic bone disease
Q91999308	Celiac Disease and Its Role in the Development of Metabolic Bone Disease
Q35216533	Cell therapy for bone disease: a review of current status
Q36925346	Cellular mechanisms of multiple myeloma bone disease
Q80422704	Cemented endoprosthetic replacement for metastatic bone disease in the proximal femur
Q92523800	Challenges in comparing physical abuse, fractures and metabolic bone disease in young children in the UK and Sweden
Q37660436	Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy
Q66696198	Changes in Protein-Bound Calcium During Haemodialysis in Relation to Bone Disease
Q71605529	Changes in plasma bone GLA protein during treatment of bone disease
Q44313214	Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate
Q87041745	Chapter 5: Evaluation and treatment of kidney transplant bone disease
Q24805818	Chemical and biomechanical characterization of hyperhomocysteinemic bone disease in an animal model
Q40111270	Child abuse and metabolic bone disease: are they often confused?
Q69482471	Childhood uremic bone disease
Q54140330	Chloride, but not unmeasured anions, is correlated with renal bone disease markers.
Q69594543	Choanal atresia: early management and an association with marble bone disease
Q37322123	Cholestasis and metabolic bone disease - a clinical review
Q33569957	Chondrocalcinosis in primary hyperparathyroidism. Influence of age, metabolic bone disease, and parathyroidectomy
Q71481944	Chondrodystrophic myotonia: report of two cases. Myotonia, dwarfism, diffuse bone disease, and unusual ocular and facial abnormalities
Q44378886	Chromatographic analysis of urinary amino acids in Paget's disease. I : Biochemical study. Isolation and amino acid composition of a urinary peptide specific to this bone disease
Q91995204	Chronic Kidney Disease: Treatment of Comorbidities I: (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease)
Q90314921	Chronic Pancreatitis and Bone Disease
Q28544438	Chronic inflammatory disease and osteopathy: a systematic review
Q47846101	Chronic kidney disease, mineral bone disease and future risk of peripheral artery disease: Do associations rule?
Q79300687	Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1
Q67797370	Chronic renal failure: renal bone disease
Q38700803	Chronic sole ulcerations associated with degenerative bone disease in two Asian elephants (Elephas maximus).
Q80865463	Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications
Q36232629	Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment
Q88444427	Classical metaphyseal lesions thought to be pathognomonic of child abuse are often artifacts or indicative of metabolic bone disease
Q68724069	Clinical and biochemical features of aluminum-related bone disease
Q70145652	Clinical and histologic features of iron-related bone disease in dialysis patients
Q43953667	Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome
Q70789943	Clinical and metabolic studies of Paget's bone disease treated with thyrocalcitonin (author's transl)
Q50751292	Clinical and radiological features of bone disease in long-term (15 or more years) hemodialysis patients.
Q68724169	Clinical assessment of metabolic bone disease
Q48408434	Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
Q91423991	Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget's bone disease
Q67889762	Clinical experience with two simple methods of measurement of 99mTc-methylene diphosphonate body retention in bone disease
Q70006976	Clinical features of aluminum-associated bone disease in long-term hemodialysis patients
Q34576366	Clinical features of metastatic bone disease and risk of skeletal morbidity
Q83828765	Clinical outcomes of recipients with aplastic bone disease after renal transplantation
Q93649472	Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease
Q51900881	Clinical software for the assessment of trabecular bone disease in distal radius based on a magnetic resonance structural analysis.
Q41148861	Clinically available evaluation of bone disease in breast cancer--validity and cost effectiveness
Q28341997	Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma
Q30415157	Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease
Q72811470	Coincidence of vitiligo and Paget's bone disease in a patient
Q83084680	Combined technique for the correction of lower-limb deformities resulting from metabolic bone disease
Q37781071	Combined therapies of bone disease with bisphosphonates.
Q52124505	Comments on "A congenital bone disease of unknown etiology".
Q96824419	Communication in surgical decision-making while managing metastatic bone disease: matching patient expectations with surgical goals
Q63807093	Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology
Q55311492	Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue.
Q69627862	Comparative effects of alfacalcidol and parathyroidectomy with vitamin D in hyperparathyroid renal bone disease
Q69783806	Comparative imaging. Massive osteolysis (Gorham's syndrome, disappearing bone disease)
Q36718837	Comparing the Effects of Two Feeding Methods on Metabolic Bone Disease in Newborns with Very Low Birth Weights
Q58704661	Comparison of 1.5- and 3.0-T magnetic resonance imaging for evaluating lesions of the knee: A systematic review and meta-analysis (PRISMA-compliant article)
Q53736196	Comparison of Intact Parathyroid Hormone, Alkaline Phosphatase, Phosphate Levels for Diagnosing Severe Metabolic Bone Disease in Infants with Severe Bronchopulmonary Dysplasia.
Q66406681	Comparison of Two Manual Therapy Techniques on Ankle Dorsiflexion
Q73833524	Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease
Q51538830	Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
Q67947879	Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients
Q38101587	Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review
Q92205530	Compartmental Model for 223Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer
Q56922581	Complications and side effects. French researchers study bone disease
Q37170895	Complications of cemented long-stem hip arthroplasty in metastatic bone disease revisited
Q73835318	Components of biological variation of biochemical markers of bone turnover in Paget's bone disease
Q69543757	Computed tomographic assessment of metabolic bone disease
Q69187945	Computer-assisted diagnosis of metabolic bone disease using biochemistry test results
Q84247815	Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer
Q68092902	Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease
Q37853723	Consensus on the utility of bone markers in the malignant bone disease setting
Q46696878	Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients
Q34418934	Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
Q42542429	Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners
Q38167324	Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners.
Q50536180	Continued bone disease and symptoms post-parathyroidectomy.
Q69044726	Contribution of surgical radiology in the etiologic diagnosis of infectious sacro-iliitis. Apropos of 9 cases
Q72116689	Contribution to the study of Engelmann's disease
Q39523449	Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?
Q34619600	Control of uremic bone disease: role of vitamin D analogs
Q70272016	Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients
Q47293041	Copper deficiency presenting as metabolic bone disease in extremely low birth weight, short-gut infants
Q50531502	Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study.
Q87121071	Corrigendum to "Risk factors for developing mineral bone disease in phenylketonuric patients" [Mol. Genet. Metab. 108 (2013) 149-154]
Q88897393	Corrigendum to "SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice" [Bone 82 (2016) 101-107]
Q36116152	Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Q46663474	Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies
Q52037009	Coupling of porcine bone blood flow and metabolism in high-turnover bone disease measured by [(15)O]H(2)O and [(18)F]fluoride ion positron emission tomography.
Q50578105	Cranial sclerosis with striated bone disease (osteopathia striata).
Q93204389	Craniofacial skeleton of MEXICAN tetra (Astyanax mexicanus): As a bone disease model
Q71163599	Crippling bone disease in a 15-year-old girl treated by haemodialysis
Q67431785	Crohn's colitis associated with granulomatous bone disease
Q38777788	Cross-Sectional Study Evaluating Skin, Hair, Nail, and Bone Disease in Patients with Focal Dermal Hypoplasia
Q26748795	Crucial Role of Vitamin D in the Musculoskeletal System
Q70904161	Cryptococcal bone disease: a manifestation of disseminated cryptococcosis
Q44415463	Curative effects of 1.ALPHA.-hydroxycholecalciferol on calcium metabolism and bone disease in patients with chronic renal failure
Q31037297	Current concepts in pediatric bone disease
Q40663659	Current concepts in the management of disseminated malignant bone disease in childhood
Q68708092	Current concepts in the medical management of metabolic bone disease
Q34550341	Current use of autologous adipose tissue-derived stromal vascular fraction cells for orthopedic applications
Q37888604	Custom endoprosthetic reconstruction for malignant bone disease in the humeral diaphysis.
Q97588648	Cutibacterium acnes and autoinflammatory bone disease: Case series of three patients
Q37384171	Cystic angiomatosis, a heterogeneous condition: Four new cases and a literature review
Q81246788	Cystic fibrosis and bone disease: are we missing a genetic link?
Q87440558	Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator
Q91076665	Cystic fibrosis bone disease treatment: Current knowledge and future directions
Q91076660	Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications
Q86073896	Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?
Q35234582	Cystic fibrosis-related bone disease explored using a four step algorithm.
Q30948206	Cystic fibrosis-related bone disease in children: Examination of peripheral quantitative computed tomography (pQCT) data.
Q33771634	Cystic fibrosis-related bone disease: insights into a growing problem
Q69472055	Cytochemical localization of alkaline and acid phosphatase in human vanishing bone disease
Q85124133	Cytokines in bone diseases. Cytokines and myeloma bone disease
Q73490419	Cytokines, growth factors, and metabolic bone disease
Q46348547	D-lactate and metabolic bone disease in patients receiving long-term parenteral nutrition
Q50161513	DIFFERENTIATION BETWEEN THE ELECTROPHORETIC PATTERN OF SERUM ALKALINE PHOSPHATASE IN BONE DISEASE AND IN LIVER DISEASE
Q78507635	DISAPPEARING bone disease
Q37319460	Daptomycin in bone and joint infections: a review of the literature
Q70541030	Deconvolution analysis of 99mTc-methylene diphosphonate kinetics in metabolic bone disease
Q79573461	Decreased in vitro osteoblast proliferation and low turnover bone disease in nonuremic proteinuric patients
Q42218749	Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease
Q68206950	Deferoxamine Test and PTH Serum Levels Are Useful Not to Recognize but to Exclude Aluminum-Related Bone Disease
Q69672962	Deferoxamine test and bone disease in dialysis patients with mild aluminum accumulation
Q83248897	Degenerative bone disease: findings in 18 cases with posterior spurs of the lumbar vertebrae
Q99565639	Dendritic cell derived exosomes loaded with immunoregulatory cargo reprogram local immune responses and inhibit degenerative bone disease in vivo
Q96307982	Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis
Q50048429	Denosumab for myeloma bone disease: ready for prime time?
Q37970800	Denosumab for the management of bone disease in patients with solid tumors
Q47886613	Denosumab for the treatment of bone disease in solid tumors and multiple myeloma
Q50048434	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Q34323123	Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance.
Q44789196	Dermatitis herpetiformis: no evidence of bone disease despite evidence of enteropathy.
Q45923389	Description and Impact of Clinical Pharmacy Services in a Dialysis Unit: Focusing on Anemia Management and Bone Disease Management.
Q69704300	Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease
Q44768382	Destructive bone disease in early syphilis
Q73830906	Detection of bone disease with ultrasound--comparison with bone densitometry
Q70230046	Deterioration of renal bone disease in patients treated with salmon calcitonin
Q41039773	Determinants of Severe Metabolic Bone Disease in Very Low-Birth-Weight Infants with Severe Bronchopulmonary Dysplasia Admitted to a Tertiary Referral Center
Q46201870	Determination of N-ethylglycine in urine of cancer patients with metastatic bone disease by HPLC using 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride as a fluorescent labeling reagent
Q59291608	Developing a cure for Black Bone Disease
Q95929567	Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up
Q38667546	Development of Bone Targeting Drugs.
Q30852321	Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease
Q28538391	Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging
Q38132201	Development of composite scaffolds for load-bearing segmental bone defects
Q44931533	Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure
Q44629809	Development, validation and characterization of a novel mouse model of Adynamic Bone Disease (ABD).
Q37598687	Diabetes mellitus and bone disease in cystic fibrosis
Q26852990	Diabetes mellitus related bone metabolism and periodontal disease
Q68032392	Diabetic bone disease
Q73598822	Diagnosis and clinical management of metabolic bone disease
Q27011865	Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement
Q39660401	Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine
Q40317137	Diagnosis of bone disease by core biopsies.
Q35909775	Diagnosis of malignant bone disease with strontium-87m scans.
Q50223037	Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients: A Primary Study Evaluating the Usefulness of 18F-Sodium Fluoride (NaF) PET-CT.
Q77758156	Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Q69432474	Diagnostic imaging in bone disease
Q71019971	Diagnostic radiology and the pathology of bone disease
Q71778921	Diagnostic value of trephine biopsy in bone disease
Q70315694	Dialysate aluminium concentration and renal bone disease
Q66966990	Dialysis Bone Disease in Childhood: Treatment with 25-Hydroxycholecalciferol
Q71816416	Dialysis bone disease
Q43953410	Dialysis bone disease associated with other factors
Q68113708	Dialysis bone disease associated with secondary hyperparathyroidism
Q67064160	Dialysis bone disease in children. Six cases (author's transl)
Q40325017	Dialysis encephalopathy and osteomalacic bone disease: a case-controlled study
Q39377975	Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis
Q69596080	Dialysis-associated bone disease
Q69940511	Diaphyseal bone disease: scintigraphic-radiographic correlation
Q34049686	Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention
Q104564956	Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type
Q47691968	Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.
Q89824526	Differential Pain-Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma
Q68662565	Differential diagnosis of an obscure bone disease in an infant rhesus monkey
Q77549608	Differentiation of malignant and degenerative benign bone disease using Tc-99m MDP and Tc-99m citrate scintigraphy
Q92420430	Diffuse, fracturing systemic skeletal histiocytosis of unknown type: a novel metabolic bone disease
Q37694165	Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring
Q68679080	Dihydrotachysterol and calcitriol in long-term dialyzed patients with renal bone disease
Q72822241	Diphosphonates in the evaluation of metabolic bone disease
Q68093612	Direct sagittal CT in the evaluation of temporal bone disease
Q73733262	Disappearance of 99mTc-MDP accumulation in metastatic bone disease during bone scintigraphy
Q69793011	Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum
Q72240264	Disappearing Bone Disease, Morbus Gorham:Report of a Case
Q78762595	Disappearing bone disease
Q73827107	Disappearing bone disease (Gorham-stout disease): report of a case with a follow-up of 48 years
Q84339482	Disappearing bone disease and Chiari I malformation
Q38599265	Disappearing bone disease of the humerus and the cervico-thoracic spine: a case report with 42-year follow-up.
Q40818404	Disappearing bone disease of the upper extremity
Q71844361	Disappearing bone disease with arthropathy and severe scarring of the skin. A report of four cases seen in South Vietnam
Q72121382	Disappearing bone disease: a case report
Q39778641	Disappearing bone disease: a case report and review of the literature
Q69531337	Disappearing bone disease: massive osteolysis of the ribs treated with radiotherapy. Report of a case
Q47153098	Discordance between hormone receptor profile of primary breast cancer and metastatic bone disease: should bone marrow biopsy be considered a standard of care?
Q39179278	Discriminative Features in Three Autosomal Recessive Cutis Laxa Syndromes: Cutis Laxa IIA, Cutis Laxa IIB, and Geroderma Osteoplastica
Q49917786	Disentangling the association between diabetes and bone disease - Authors' reply
Q78924364	Disorders of calcium and phosphate metabolism and metabolic bone disease
Q33989156	Disturbances of acid-base balance and bone disease in end-stage renal disease
Q46789499	Does homocysteine contribute to bone disease in hyperparathyroidism?
Q68062941	Does immunosuppressive therapy influence the recovery of bone disease in kidney transplant recipients?
Q34996515	Does metabolic bone disease follow truncal vagotomy and gastrojejunostomy?
Q70461969	Does metabolic bone disease follow truncal vagotomy and gastrojejunostomy?
Q46111175	Does taurine deficiency cause metabolic bone disease and rickets in polar bear cubs raised in captivity?
Q50854438	Does transient hypothyroxinemia influence metabolic bone disease of prematurity?
Q71849019	Does uremic bone disease warrant early treatment with calcitriol?
Q77833662	Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease
Q90146197	Drug Delivery Based on Nanotechnology for Target Bone Disease
Q52802657	Drug-eluting implants for the suppression of metastatic bone disease: current insights.
Q93687674	Dynamic Studies of Metabolic Bone Disease
Q88649847	Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner
Q73181679	Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
Q79299868	Early kidney transplantation may prevent aluminium-related bone disease
Q69575482	Early therapy of renal bone disease with calcitriol: a prospective double-blind study
Q73597738	Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
Q80196858	Economic burden of metastatic bone disease in the U.S.
Q82147375	Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil
Q46388111	Ectopic calcification in patients with aplastic bone disease undergoing dialysis
Q67264542	Editorial: Diphosphonate treatment in bone disease
Q44172707	Editorial: Fluoride and bone disease in uremia
Q67784341	Editorial: Metabolic bone disease in Asians
Q45261649	Editorial: Working towards an understanding of bone disease in HIV.
Q38246385	Educational intervention for metabolic bone disease in patients with chronic kidney disease: a systematic review and meta-analysis
Q39523756	Edward Neuhauser memorial lecture. Genetic bone disease: radiologic sight and insight
Q61804736	Effect of Osteoking on the osteogenic and adipogenic differentiation potential of rat bone marrow mesenchymal stem cells in vitro
Q26774371	Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic Review
Q36902283	Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
Q42869501	Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Monitoring the calcium-phosphate product is important
Q42868876	Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism
Q46364915	Effect of alfacalcidol on renal bone disease in mild to moderate renal failure: Authors’ reply
Q70459871	Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat
Q45383290	Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women
Q67827234	Effect of dialysate calcium concentration on bone disease in patients on hemodialysis
Q44564971	Effect of fluoride on aluminum-induced bone disease in rats with renal failure
Q41330378	Effect of high-dose vitamin D supplementation on radiographically detectable bone disease of very low birth weight infants
Q50021375	Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study
Q79920093	Effect of lowering dialysate calcium on bone and mineral parameters related to adynamic bone disease
Q42633617	Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Q43627794	Effect of parathyroidectomy on aluminum toxicity and azotemic bone disease in the rat.
Q67240369	Effect of treatment of calcium kinetics in metabolic bone disease
Q95323068	Effect on metabolic bone disease markers in the neonatal intensive care unit with implementation of a practice guideline
Q36773617	Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review
Q53711912	Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
Q71132228	Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients
Q78790961	Effects of Mytatrienediol in Multiple Myeloma, Metastatic Bone Disease, and Osteoporosis
Q66405338	Effects of Osteopathic Techniques on Residual Volume in Severe Chronic Obstructive Pulmonary Disease
Q68839179	Effects of age, sex, and polycystic disease on progressive bone disease of renal failure
Q36810095	Effects of anticonvulsants and inactivity on bone disease in epileptics
Q46905043	Effects of bone disease and calcium supplementation on antioxidant enzymes in postmenopausal women
Q46230939	Effects of bortezomib on bone disease in multiple myeloma
Q68431594	Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure
Q44309586	Effects of dialysate calcium and fluoride on bone disease during regular hemodialysis
Q28535084	Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?
Q95721254	Effects of in-center daily hemodialysis upon mineral metabolism and bone disease in end-stage renal disease patients
Q43700291	Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
Q78163821	Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease
Q45777666	Effects of prolonged immobilization on sequential changes in mineral and bone disease parameters
Q60534579	Effects of risedronate on metabolic bone disease in patients with type 1 diabetes and osteoporosis
Q48314232	Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Q97093232	Effects of the dialysate calcium concentrations and mineral bone disease treatments on mortality in The French Renal Epidemiology and Information Network (REIN) registry
Q26769030	Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis
Q44346550	Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study
Q44445062	Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia
Q38123649	Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers
Q33226448	Efficacy of ibandronate in metastatic bone disease: review of clinical data
Q28468654	Efficacy of oral etidronate for skeletal diseases in Japan
Q93690692	Efficacy of the bisphosphonate APD in the control of Paget's bone disease
Q69683983	Elderly people: metabolic bone disease
Q91306951	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease
Q24805068	Emerging strategies of bone and joint repair
Q30399653	Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor
Q33895000	Endemic chronic fluoride toxicity and dietary calcium deficiency interaction syndromes of metabolic bone disease and deformities in India: year 2000.
Q53758479	Endemic skeletal fluorosis and metabolic bone disease (a radiological and morphometrical study of bone).
Q45160095	Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major.
Q24671004	Endocrine bone disease
Q37887890	Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Q85266398	Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major
Q70034964	Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure
Q47760635	Endothelin-1 and Paget's bone disease: is there a link?
Q39395547	Engineering 3D Models of Tumors and Bone to Understand Tumor-Induced Bone Disease and Improve Treatments
Q43586954	Environmental bone disease of hitherto undescribed type.
Q64088142	Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease
Q35863224	Eradication of advanced pelvic hydatid bone disease after limb salvage surgery - 5-year follow-up: a case report
Q47900533	Erdheim-Chester disease and radiobiphosphonates bone scan: from a simple peripheral form to a rare axial location: A case report
Q87046594	Erratum to: Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice
Q35938872	Estimated number of prevalent cases of metastatic bone disease in the US adult population
Q37767123	Estrogens and bone disease in chronic kidney disease: role of FGF23.
Q82552160	Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy
Q34497878	Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibility
Q34058192	Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors
Q34058225	Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone
Q37218101	Evaluation and management of bone disease and fractures post transplant
Q51118853	Evaluation and treatment of bone disease after fragility fracture.
Q107508137	Evaluation of Alerts in Promoting Bone Densitometry Scans
Q40274859	Evaluation of Bone Disease in Kidney Transplant Recipients
Q43773534	Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss
Q56993837	Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation
Q77844510	Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios
Q44170314	Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients
Q64930816	Evaluation of bone disease in patients with cystic fibrosis and end-stage lung disease.
Q41578462	Evaluation of factors related to bone disease in Polish children and adolescents with cystic fibrosis
Q73818164	Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions
Q97651731	Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV
Q67669224	Evidence for a relationship between plasma immunoreactive calcitonin and bone disease in chronic renal failure
Q68009763	Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease
Q72898122	Evidence for abnormal calcium homeostasis in patients with adynamic bone disease
Q37935402	Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article
Q36538536	Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients
Q93524366	Evolution of Bone Disease
Q53412995	Evolution of bone disease after kidney transplantation: A prospective histomorphometric analysis of trabecular and cortical bone.
Q43254714	Evolution of bone disease at 2 years after transplantation: a single-center study
Q69618487	Evolution of bone disease over 10 years in 135 patients with terminal renal failure
Q45766538	Evolving treatment patterns for metastatic bone disease: the role of SBRT: in regard to Olson et al and Ellsworth et al.
Q68845638	Exogenous calcitonin protects against renal bone disease in rats with early renal failure
Q91492730	Exosomes and Bone Disease
Q58575853	Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
Q70194765	Experience with aluminum-associated bone disease in end-stage renal disease patients
Q39732285	Experimental aluminum-induced bone disease: studies in vivo
Q52952110	Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Q36822450	Extent of Surgery Does Not Influence 30-Day Mortality in Surgery for Metastatic Bone Disease: An Observational Study of a Historical Cohort
Q58085623	Extraskeletal Osteoclastomas Responsive to Dexamethasone Treatment in Paget Bone Disease
Q73853160	Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease
Q90822790	FGF23-Related Hypophosphataemic Bone Disease
Q68573003	Factors influencing the development of metabolic bone disease in primary biliary cirrhosis
Q67063578	Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease
Q79424772	Familial bone disease resembling rickets (hereditary metaphysial dysostosis)
Q62117550	Femoral Neck Stress Fractures and Metabolic Bone Disease
Q57904558	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
Q90628563	Findings of metabolic bone disease in infants with unexplained fractures in contested child abuse investigations: a case series of 75 infants
Q58568987	First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease
Q93962982	Fluoride and Bone Disease
Q93966047	Fluoride and Bone Disease
Q82943583	Fluoride therapy for bone disease
Q93764918	Fluoride therapy for pain in malignant bone disease
Q80432831	Fluoride-related bone disease associated with habitual tea consumption
Q38400321	Fluorosis as a probable factor in metabolic bone disease in captive New Zealand native frogs (Leiopelma species).
Q39048108	Fluorotoxic metabolic bone disease: an osteo-renal syndrome caused by excess fluoride ingestion in the tropics
Q93696522	Fluride and Bone Disease
Q71246069	Follow-up of long-term treatment of predialysis renal bone disease with 1-alpha-hydroxy-derivatives of vitamin D
Q92612435	Forgotten signs of chronic kidney disease-associated mineral bone disease
Q37407087	Founders lecture 2007: Metabolic bone disease: what has changed in 30 years?
Q78285123	Four unusual cases of temporal bone disease
Q39418052	Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA).
Q71823132	Fracture healing in metastatic bone disease
Q69585220	Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment
Q90256730	Fracture risk assessment and clinical decision making for patients with metastatic bone disease
Q53374492	Fractures Related to Metabolic Bone Disease in Children with Congenital Heart Disease.
Q33793343	Fractures secondary to nutritional bone disease in dogs: a review of 38 cases.
Q101227095	Fragile and Brittle Bone Disease or Osteogenesis Imperfecta: A Case Report
Q90779138	Frailty Is an Independent Risk Factor for Mortality, Cardiovascular Disease, Bone Disease, and Diabetes Among Aging Adults With Human Immunodeficiency Virus
Q92774912	Free 25-Vitamin D Is Correlated with Cardiovascular Events in Prevalent Hemodialysis Patients but Not with Markers of Renal Mineral Bone Disease
Q71163654	Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients--retrospective analysis of 1429 iliac crest biopsies
Q43504517	Frequency of metabolic bone disease in haemodialysis patients
Q90803379	From Crosstalk between Immune and Bone Cells to Bone Erosion in Infection
Q26764854	From disease to treatment: from rare skeletal disorders to treatments for osteoporosis
Q92352305	Functional outcome of operative treatment for pelvic metastatic bone disease from primary thyroid cancer: A case series
Q92783676	Further Defining the Phenotypic Spectrum of B3GAT3 Mutations and Literature Review on Linkeropathy Syndromes
Q79564645	Further observations on the Kenhardt bone disease and its relation to flurosis
Q78477770	GLYCYL-PROLINE IN URINE OF HUMANS WITH BONE DISEASE
Q64218075	Gain-of-function mutations in a member of the Src family kinases cause autoinflammatory bone disease in mice and humans
Q72256516	Galactosyl hydroxylysine in assessment of Paget's bone disease
Q73909415	Gastric surgery-induced alterations of gastrinemia--role in the onset or prevention of postgastrectomy bone disease
Q83592602	Gender differences in the prevalence and severity of bone disease in thalassaemia
Q87641669	Gene expression changes in cancellous bone of type 2 diabetics: a biomolecular basis for diabetic bone disease
Q73928876	Generalised bone disease with abundant periosteal reaction in megakaryocytic leukaemia
Q53701286	Generalized metabolic bone disease and fracture risk in Rothmund-Thomson syndrome.
Q30841192	Generalized metabolic bone disease in Neurofibromatosis type I
Q47141750	Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth
Q34674841	Genetic factors influencing the risk of multiple myeloma bone disease
Q36934224	Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Q58978431	Genetics cracks bone disease
Q93523834	Genetics of Bone Disease
Q78613981	Giant solitary parathyroid adenoma presenting with bone disease
Q35607935	Gorham Stout syndrome (disappearing bone disease): two additional case reports and a review of the literature
Q91881886	Gorham-Stout Syndrome: A Phantom Bone Disease Treated With Bisphosphonates
Q91706495	Grade I meningioma with disseminated bone disease: a rare clinical phenomenon
Q72003034	Gross displacement of the mandibular canal: a radiographic sign of benign fibro-osseous bone disease
Q53877790	Ground water fluorosis: detection of a new endemic focus. The significance of biological levels of fluoride
Q80788528	Growth failure and metabolic bone disease in progressive familial intrahepatic cholestasis
Q67857399	Guidelines for clinical trials in osteoporosis. A position paper of the European Foundation for Osteoporosis and Bone Disease
Q38307158	HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.
Q37304461	HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection
Q30249771	HIV infection and bone disease
Q37962710	HIV infection and bone disease: implications for an aging population
Q42378329	HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice
Q50658438	Half-body single photon emission computed tomography with resolution recovery for the evaluation of metastatic bone disease: implementation into routine clinical service.
Q91399594	Has Paget's bone disease become rare?
Q81395587	Have myeloma cells osteoclast-like activity? Implications into the pathogenesis of myeloma bone disease
Q52983838	Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT.
Q34629902	Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol
Q71134854	Healing of lytic Paget bone disease with diphosphonate therapy
Q96130584	Heart failure is associated with accelerated age related metabolic bone disease
Q52136927	Help! Unusual X-ray appearances of a congenital bone disease of unknown aetiology.
Q48521210	Hemiarthroplasty for Fractures of Metastatic Bone Disease Have Different Outcomes Compared to Fractures Without Metastasis: A Matched-Pair Analysis
Q43621162	Hemodialysis bone disease: correlation between clinical, histologic, and other findings
Q79563383	Hepatic alkaline phosphatase; histological and microchemical studies on liver tissue in normal subjects and in liver and in bone disease
Q79154186	Hereditary elastodystrophy ("pseudoxanthoma elasticum") and bone disease
Q57757152	Heritable Bone Disease and Stroke due to Vertebral Artery Dissection
Q88114533	Heterogeneous pattern of bone disease in adult type 1 Gaucher disease: clinical and pathological correlates
Q36162776	High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Q34377567	High and low turnover bone disease in patients on chronic peritoneal dialysis
Q50927303	High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population.
Q80464456	High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients
Q50856578	High turnover bone disease following lung transplantation.
Q42153927	Hip changes in metabolic bone disease
Q68244163	Histiocytosis X in children. Apropos of 22 cases
Q80598175	Histologic evolution of bone disease 6 months after successful kidney transplantation
Q70426426	Histological study of navicular bone disease
Q52263855	Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas.
Q93701468	Human calcitonin in the treatment of Paget's bone disease
Q62003041	Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
Q36107856	Hungry bone disease in a pregnant woman with parathyroid adenoma
Q83487823	Hydatid bone disease of the femur
Q36238429	Hydatid bone disease of the pelvis. A report of two cases and review of the literature
Q36347318	Hydatid bone disease: a case report and review of the literature
Q72535523	Hypercalcaemia and metastatic bone disease: is there a causal link?
Q57224655	Hypercalcemia and pancreatitis in a child with adynamic bone disease
Q91623319	Hypereosinophilia and severe bone disease in an African child: an unexpected diagnosis
Q47640341	Hyperostotic bone disease in a wombat (Vombatus ursinus).
Q78602095	Hyperostotic bone disease in red pandas (Ailurus fulgens)
Q69813240	Hyperparathyroid bone disease in children undergoing long-term hemodialysis; treatment with vitamin D
Q36749771	Hyperparathyroid bone disease in chronic renal failure
Q44610132	Hyperparathyroid bone disease in diabetic renal failure.
Q49986427	Hyperparathyroidism Mimicking Metastatic Bone Disease: A Case Report and Review of Literature
Q73026050	Hyperparathyroidism and bone disease after renal transplantation
Q69535055	Hypocalcaemia and Bone Disease in Renal Failure
Q40817006	Hypocalcaemia in patients with metastatic bone disease treated with denosumab
Q69267362	Hypocalcemia complicating deferoxamine therapy in an infant with parenteral nutrition-associated aluminum overload: evidence for a role of aluminum in the bone disease of infants
Q70193468	Hypocalcemia in metastatic bone disease: metabolic and radionuclide studies of a case
Q63729113	Hyponatremia and metabolic bone disease in patients with epilepsy
Q64112718	Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study
Q45984452	Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH.
Q70622240	Hypophosphatemia and osteoblast function in human bone disease
Q98830309	Hypophosphatemia as an Early Metabolic Bone Disease Marker in Extremely Low Birth Weight Infants After Prolonged Parenteral Nutrition Exposure
Q90328940	Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm
Q44488206	Hypophosphatemic nonrachitic bone disease: An entity distinct from X-linked hypophosphatemia in the renal defect, bone involvement, and inheritance
Q59793642	Hypoxic Microenvironment and Metastatic Bone Disease
Q67833099	Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease
Q66916246	I alpha-hydroxycholecalciferol: a treatment of renal bone disease
Q55121772	IL-20 bone diseases involvement and therapeutic target potential.
Q43574440	Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma
Q30980760	Ibandronate in metastatic bone disease: a review of preclinical data
Q74462987	Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
Q35650666	Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials
Q58868253	Identification of Metabolic Bone Disease in Patients with Endogenous Hyperthyroidism: Role of Biological Markers of Bone Turnover
Q80233991	Identification of N-ethylglycine in urine of cancer patients with metastatic bone disease
Q36264820	Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
Q38427573	Identifying informative risk factors and predicting bone disease progression via deep belief networks
Q71055771	Iliopsoas bursitis-an unusual presentation of metastatic bone disease
Q92545643	Image Diagnosis: Disappearing Digits: Metabolic Bone Disease in End-Stage Renal Disease
Q56866868	Imaging Findings and Evaluation of Metabolic Bone Disease
Q88528795	Imaging Findings of Metabolic Bone Disease
Q58768770	Imaging features and differential diagnosis of multiple diaphyseal sclerosis: A case report and review of literature
Q78831062	Imaging in metabolic bone disease
Q37605543	Imaging metastatic bone disease from carcinoma of the prostate
Q89914793	Imaging of metabolic bone disease
Q34363578	Imaging of metabolic bone disease and marrow disorders in children
Q61043820	Immunomodulation of Multiple Myeloma Bone Disease
Q61043818	Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone Disease
Q80437808	Immunosuppressant drugs and bone disease: a clinician's perspective
Q43037617	Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia.
Q50335307	Impact of Early Versus Late Diuretic Exposure on Metabolic Bone Disease and Growth in Premature Neonates
Q67128613	Impact of Osteopathy on Pain After Breast Cancer Surgery
Q49989147	Impact of bone disease and pain in thalassemia
Q36697318	Impact of kidney bone disease and its management on survival of patients on dialysis
Q57217879	Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease
Q39086345	Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Q56999706	Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease
Q38187206	Impact of standardized feeding guidelines on enteral nutrition administration, growth outcomes, metabolic bone disease, and cholestasis in the NICU.
Q91116115	Impaired Gastric Hormone Regulation of Osteoblasts and Lysyl Oxidase Drives Bone Disease in Diabetes Mellitus
Q62071796	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells
Q89589984	Importance of osteocyte-mediated regulation of bone remodelling in inflammatory bone disease
Q50543803	Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm.
Q73136353	Improved functional endpoints for use in vitamin K assessment: important implications for bone disease
Q44976160	Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Q82208542	Improvement of adynamic bone disease after renal transplantation
Q57221130	Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium
Q36737076	Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
Q71348422	Improvement of bone disease with increased dose of glucocerebrosidase in a Gaucher disease patient who had a bone lesion presenting during low-dose enzyme replacement therapy
Q71804255	Improvement of early renal bone disease with alfacalcidol therapy
Q49819612	Incidence of metabolic bone disease in preterm infants of birth weight <1250 g and in those suffering from bronchopulmonary dysplasia
Q70379704	Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis
Q38162876	Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents
Q90997914	Incidence of surgical interventions for metastatic bone disease in the extremities: a population-based cohort study
Q71958652	Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxyvitamin D levels. Implications for metabolic bone disease
Q57904674	Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
Q54535110	Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.
Q36478430	Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Q37334608	Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome
Q68724079	Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH
Q54032619	Influence of adynamic bone disease on responsiveness to recombinant human erythropoietin in peritoneal dialysis patients.
Q80305583	Influence of genetic polymorphisms on bone disease of preterm infants
Q39915275	Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Q57226001	Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease
Q39758292	Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma
Q91584944	Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells
Q80314458	Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma
Q38096641	Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis
Q93249136	Insights on dietary omega-6/omega-3 polyunsaturated fatty acid (PUFA) ratio in oxidative metabolic pathways of oncological bone disease and global health
Q35097641	Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
Q78166901	Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease
Q80347072	Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis
Q90788171	Integrating the immune microenvironment of prostate cancer induced bone disease
Q36001776	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease
Q36688447	Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis
Q46065491	Intercalary bone grafting for the reconstruction of phalangeal osteolysis in disappearing bone disease: case report
Q35989786	Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.
Q90466060	Interventions for Preventing Bone Disease Following Kidney Transplantation: Is There Evidence for Specific Therapy?
Q90466070	Interventions for Preventing Bone Disease in Kidney Transplant Recipients: Editorial Summary of a Cochrane Review
Q24240712	Interventions for bone disease in children with chronic kidney disease
Q24187788	Interventions for metabolic bone disease in children with chronic kidney disease
Q24243851	Interventions for preventing bone disease in kidney transplant recipients
Q24243926	Interventions for preventing bone disease in kidney transplant recipients
Q24246949	Interventions for preventing bone disease in kidney transplant recipients
Q90866122	Interventions for preventing bone disease in kidney transplant recipients
Q36087152	Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials
Q74521205	Intra-cortical diaphyseal Brodie abscess of the long bones. Four cases
Q83051551	Intractable seizures and metabolic bone disease secondary to celiac disease
Q68718257	Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease
Q42878212	Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Q52653692	Investigating the efficacy of bisphosphonates treatment against multiple myeloma induced bone disease using a computational model.
Q44183215	Investigation of bone disease using isomerized and racemized fragments of type I collagen
Q79319075	Investigation of hyperparathyroidism in the absence of bone disease
Q67952027	Iron overload and bone disease in chronic dialysis patients
Q68385254	Iron overload and bone disease in chronic dialysis patients
Q81535187	Is aluminum related bone disease common in hemodialysis units using aluminum based phosphate binders?
Q33866456	Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study
Q43472893	Is there any association between the presence of bone disease and cumulative exposure to lead?
Q104286079	Is whole body low dose CT still necessary in the era of ¹⁸F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients?
Q34619408	Issues of malnutrition and bone disease in patients with cirrhosis
Q68689158	Jejunal calcium transport in health and metabolic bone disease: Effect of vitamin D
Q36471769	Joint and bone disease due to mycotic infection
Q73924850	Joint and bone disease due to mycotic infection
Q45299603	Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models
Q46815338	K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.
Q76575194	KINETICS OF HUMAN CITRATE METABOLISM: STUDIES IN NORMAL SUBJECTS AND IN PATIENTS WITH BONE DISEASE
Q84328828	Keeping a broad approach to managing pediatric bone disease
Q33862710	Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals
Q93674284	Kinetics of aluminium removal by desferrioxamine VIA hemodialysis in a case with aluminium bone disease
Q58986895	Kinetics of the circulating levels of bone alkaline phosphatase in a case of hungry bone disease following total parathyroidectomy
Q71826056	Köhlerʼs Bone Disease of the Tarsal Navicular
Q58572512	LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens
Q36005849	LRP receptor family member associated bone disease
Q68652152	Laboratory aids in the diagnosis of metabolic bone disease
Q41180088	Laboratory assessment of nutritional metabolic bone disease in infants
Q72017291	Lack of metabolic bone disease in patients with fracture of the femoral neck
Q69734914	Latest news on metabolic bone disease
Q28085613	Lessons from Microglia Aging for the Link between Inflammatory Bone Disorders and Alzheimer's Disease
Q61311201	Lessons from the Past: Metabolic Bone Disease in Historical Captive Primates
Q42851229	Letter to the editor: Unexplained fractures: child abuse or bone disease: a systematic review
Q42925705	Letter to the editor: Unexplained fractures: child abuse or bone disease: a systematic review
Q64055497	Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation
Q72318999	Localization of bone disease with radiostrontium
Q53415196	Localized bone disease as a presentation of hairy cell leukemia.
Q97536651	Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation
Q45335110	Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy
Q101053579	Long-term follow-up of a cat with an undetermined osteoporotic bone disease managed with multiple intramedullary pins
Q81313448	Long-term survival after surgical intervention for bone disease in multiple myeloma
Q87423248	Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years
Q70985806	Losses of 25-hydroxyvitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis
Q43732037	Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients
Q35090495	Low infection rate after tumor hip arthroplasty for metastatic bone disease in a cohort treated with extended antibiotic prophylaxis
Q71164117	Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients
Q37301138	Low turn-over bone disease in patients with chronic renal disease.
Q38990530	Low turnover bone disease in Egyptian children with acute leukemia
Q67888747	Low turnover bone disease is the more common form of bone disease in CAPD patients
Q57226288	Low- and high-turnover bone disease in continuous ambulatory peritoneal dialysis: effects of low-Ca2+ peritoneal dialysis solution
Q68017907	Low-dose desferrioxamine test for the diagnosis of aluminium-related bone disease in patients on regular haemodialysis
Q40553379	Low-protein diets and bone disease in chronic renal failure
Q54481006	Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation.
Q89248346	METABOLIC BONE DISEASE
Q41157085	METABOLIC BONE DISEASE AND REVERSIBLE RENAL TUBULAR DYSFUNCTION IN A CHRONIC ALCOHOLIC.
Q46957183	MKP-1 knockout does not prevent glucocorticoid-induced bone disease in mice
Q78238541	MYOPATHY IN METABOLIC BONE DISEASE
Q68897128	Magnesium and bone disease
Q74224080	Malabsorption and bone disease in prolonged obstructive jaundice
Q32063101	Malignant hypophosphathaemic bone disease
Q61524657	Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone
Q38858178	Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment
Q64094480	Management of Post-transplant Hyperparathyroidism and Bone Disease
Q42688826	Management of adynamic bone disease in chronic kidney disease: A brief review
Q38290826	Management of bone disease in Gaucher disease type 1: clinical practice.
Q92610445	Management of bone disease in cystinosis: Statement from an international conference
Q38179039	Management of bone disease in multiple myeloma
Q35355306	Management of bone disease in patients on long term glucocorticoid therapy
Q37926111	Management of bone disease in patients undergoing hormonal therapy for breast cancer
Q39841377	Management of bone disease in the dialysis patient
Q38619529	Management of bone disease in women after breast cancer
Q72341477	Management of metabolic bone disease
Q37085366	Management of metabolic bone disease in kidney transplant recipients
Q74303267	Management of metastatic bone disease in orthopedics
Q38087149	Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: effectiveness and safety
Q38159595	Management of metastatic bone disease of the acetabulum
Q57026820	Management of multiple myeloma bone disease: impact of treatment on renal function
Q37176146	Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
Q39374938	Managing metastatic bone disease: three case studies
Q82593420	Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update
Q42406589	Manipulating bone disease in inflammatory bowel disease patients
Q36257324	Marble Bone Disease: A Rare Bone Disorder
Q43507829	Marble bone disease
Q71291865	Marble bone disease
Q35785168	Marble bone disease and the Anaesthesiologist
Q69594534	Marble bone disease in a child
Q71225329	Marble bone disease in a family
Q70534005	Marble bone disease in adults (M. Albers-Schönberg, ostoepetrosis). I. Histochemical, polarization-optic and microradiographic studies following intravital biopsies
Q69578437	Marble bone disease with advanced osteosclerotic lesions in radiographs
Q78630049	Marble bone disease with brachydactylia
Q34716092	Marble bone disease: a review of osteopetrosis and its oral health implications for dentists.
Q83210037	Marble bone disease; a study of its relation to normal bone development
Q83322167	Marble bone disease; a study of osteogenesis
Q40975330	Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice
Q64043399	Massive Osteolysis in Distal Shaft of Humerus: A Case Report on Vanishing Bone Disease
Q87863615	Massive osteolysis in disappearing bone disease
Q89773700	Mathematical modelling of the role of Endo180 network in the development of metastatic bone disease in prostate cancer
Q55463750	Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients.
Q80165672	Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients
Q101139003	Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease
Q69692668	Mechanism for bone disease found in inhabitants environmentally exposed to cadmium: decreased serum 1 alpha, 25-dihydroxyvitamin D level
Q40913924	Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease
Q57170076	Mesenchymal Stem Cell Migration during Bone Formation and Bone Diseases Therapy
Q58720492	Mesenchymal Stem Cell Therapy for Bone Regeneration
Q26753086	Mesenchymal stem cells (MSCs) as skeletal therapeutics - an update
Q70284823	Metabolic Bone Disease And Vitamin D Deficiency In Crohn's Disease
Q91050301	Metabolic Bone Disease In Premature Neonates- An Unmet Challenge
Q61628069	Metabolic Bone Disease and Inherited Disorders of Bone and Connective Tissue
Q50300610	Metabolic Bone Disease and Related Research
Q93654128	Metabolic Bone Disease in Children
Q57169423	Metabolic Bone Disease in Gastrointestinal Disorders
Q74064664	Metabolic Bone Disease in Inflammatory Bowel Disease
Q69755246	Metabolic Bone Disease in Patients on Maintenance Hemodialysis
Q39008085	Metabolic Bone Disease in Patients with Malabsorption
Q38854351	Metabolic Bone Disease in Primary Biliary Cirrhosis
Q36961986	Metabolic Bone Disease in Viral Cirrhosis: A Prospective Study
Q37311569	Metabolic Bone Disease in preterm newborn: an update on nutritional issues
Q37649225	Metabolic Bone Disease in the Context of Metastatic Neuroendocrine Tumor: Differentiation from Skeletal Metastasis, the Molecular PET-CT Imaging Features, and Exploring the Possible Etiopathologies Including Parathyroid Adenoma (MEN1) and Paraneopla
Q38812572	Metabolic Bone Disease in the Post-transplant Population: Preventative and Therapeutic Measures
Q64119225	Metabolic Bone Disease of Prematurity: Diagnosis and Management
Q104476508	Metabolic Bone Disease of Prematurity: Risk Factors and Associated Short-Term Outcomes
Q54184179	Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment.
Q67961840	Metabolic bone disease
Q68145536	Metabolic bone disease
Q68177960	Metabolic bone disease
Q68332741	Metabolic bone disease
Q68482652	Metabolic bone disease
Q68576959	Metabolic bone disease
Q69395933	Metabolic bone disease
Q70764595	Metabolic bone disease
Q70913147	Metabolic bone disease
Q71230797	Metabolic bone disease
Q71669916	Metabolic bone disease
Q71881290	Metabolic bone disease
Q72129882	Metabolic bone disease
Q73523462	Metabolic bone disease
Q78015770	Metabolic bone disease
Q78596797	Metabolic bone disease
Q77185497	Metabolic bone disease
Q52035129	Metabolic bone disease (anticonvulsant osteomalacia) and renal tubular acidosis in tuberous sclerosis.
Q44741594	Metabolic bone disease after chronic antacid administration in an infant
Q71830476	Metabolic bone disease after gastrectomy
Q36042206	Metabolic bone disease after gastric bypass surgery for obesity
Q67364190	Metabolic bone disease after intestinal bypass for treatment of obesity
Q38188853	Metabolic bone disease after renal transplantation
Q39736456	Metabolic bone disease and Paget's disease in the elderly. Part I: Metabolic bone disease
Q70292757	Metabolic bone disease and Paget's disease in the elderly. Part II: Paget's disease
Q70039712	Metabolic bone disease and aluminium contamination in 38 uremic patients. A bone histomorphometric study
Q86939904	Metabolic bone disease and bone mineral density in very preterm infants
Q54759952	Metabolic bone disease and central retinal degeneration in a kitten due to nutritional inadequacy of an all-meat raw diet.
Q44583854	Metabolic bone disease and fractures in male alcoholics: a pilot study
Q35831980	Metabolic bone disease and parenteral nutrition
Q70597229	Metabolic bone disease and the elderly: current approach to diagnosis and therapy
Q70913492	Metabolic bone disease and the gastro intestinal tract
Q74156963	Metabolic bone disease and total parenteral nutrition: a progress report
Q37949600	Metabolic bone disease as a presenting manifestation of primary Sjögren's syndrome: Three cases and review of literature
Q66911725	Metabolic bone disease as a result of lactase deficiency
Q37287513	Metabolic bone disease associated with systemic disorders.
Q34010846	Metabolic bone disease associated with total parenteral nutrition
Q70509226	Metabolic bone disease associated with total parenteral nutrition
Q72452167	Metabolic bone disease during parenteral nutrition
Q38709152	Metabolic bone disease evaluated by a combined calcium balance and tracer kinetic study
Q43415463	Metabolic bone disease following gastrectomy: assessment by dual energy X-ray absorptiometry
Q38247356	Metabolic bone disease following urinary diversion in adults
Q67809011	Metabolic bone disease in Asians
Q58379518	Metabolic bone disease in HIV infection
Q34028096	Metabolic bone disease in IBD.
Q93228541	Metabolic bone disease in Saudi Arabian children and adolescent patients with ulcerative colitis
Q40215642	Metabolic bone disease in a patient on long-term total parenteral nutrition: a case report with review of literature
Q37208646	Metabolic bone disease in adolescents: recognition, evaluation, treatment, and prevention.
Q70746500	Metabolic bone disease in adults receiving long-term parenteral nutrition: longitudinal study with regional densitometry and bone biopsy
Q33715517	Metabolic bone disease in adults with inflammatory bowel disease
Q71004506	Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment
Q58972465	Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis
Q39895210	Metabolic bone disease in children
Q40284829	Metabolic bone disease in children : etiology and treatment options
Q99726598	Metabolic bone disease in children with intestinal failure is not associated with the level of parenteral nutrition dependency
Q36717712	Metabolic bone disease in chronic kidney disease
Q42644964	Metabolic bone disease in chronic renal failure. I. Dialyzed uremics
Q42161773	Metabolic bone disease in chronic renal failure. II. Renal transplant patients
Q36808285	Metabolic bone disease in gastrointestinal illness
Q40445114	Metabolic bone disease in gastrointestinal, hepatobiliary, and pancreatic disorders and total parenteral nutrition.
Q54679743	Metabolic bone disease in gut diseases.
Q39595608	Metabolic bone disease in home total parenteral nutrition
Q42739610	Metabolic bone disease in human immunodeficiency virus-infected children
Q35764965	Metabolic bone disease in inflammatory bowel disease
Q80238705	Metabolic bone disease in juvenile Humboldt penguins (Spheniscus humboldti): investigation of ionized calcium, parathyroid hormone, and vitamin D3 as diagnostic parameters
Q44456024	Metabolic bone disease in juvenile koalas (Phascolartcos cinereus).
Q44019992	Metabolic bone disease in long-term total parenteral nutrition
Q68569149	Metabolic bone disease in lumbar pseudarthrosis
Q92485616	Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain
Q36626332	Metabolic bone disease in patients receiving home parenteral nutrition: a Canadian study and review
Q54710976	Metabolic bone disease in patients receiving long-term total parenteral nutrition.
Q73069467	Metabolic bone disease in patients with inflammatory bowel disease
Q35046555	Metabolic bone disease in patients with liver disease
Q36206246	Metabolic bone disease in pediatric intestinal failure patients: prevalence and risk factors
Q39687549	Metabolic bone disease in premature infants
Q46962405	Metabolic bone disease in premature infants and genetic polymorphisms
Q42999313	Metabolic bone disease in preterm infants
Q69629517	Metabolic bone disease in preterm infants
Q53148493	Metabolic bone disease in preterm infants: Relationship between radiologic grading in the wrist and serum biochemical markers.
Q37804832	Metabolic bone disease in primary biliary cirrhosis
Q68249204	Metabolic bone disease in primary biliary cirrhosis at presentation
Q54450597	Metabolic bone disease in pseudohypoparathyroidism: radiologic features.
Q34497003	Metabolic bone disease in the bariatric surgery patient
Q43489260	Metabolic bone disease in the elderly
Q69107776	Metabolic bone disease in the elderly
Q44648126	Metabolic bone disease in the elderly. Biochemical studies in three different racial groups living in South Africa
Q79914935	Metabolic bone disease in the long-term parenteral nutrition patient
Q38959305	Metabolic bone disease in the preterm infant: Current state and future directions.
Q72464517	Metabolic bone disease in total parenteral nutrition
Q47309469	Metabolic bone disease in very-low-birth-weight infants: assessment, prevention, and treatment by neonatal nurse practitioners
Q38442104	Metabolic bone disease in wild collared doves (Streptopelia decaocto).
Q34429897	Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates
Q44186830	Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease
Q71354650	Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis?
Q40931623	Metabolic bone disease of prematurity
Q45759386	Metabolic bone disease of prematurity
Q69893170	Metabolic bone disease of prematurity
Q69894987	Metabolic bone disease of prematurity
Q101218419	Metabolic bone disease of prematurity - national survey of current neonatal and paediatric endocrine approaches
Q83581241	Metabolic bone disease of prematurity and secondary hyperparathyroidism
Q91951906	Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences
Q34077974	Metabolic bone disease of prematurity: report of four cases.
Q41686398	Metabolic bone disease of total parenteral nutrition.
Q44184074	Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content
Q69627992	Metabolic bone disease presenting as multiple recurrent metatarsal fractures: a case report
Q40179817	Metabolic bone disease resembling osteosarcoma in a wooly monkey (Lagothrix lagotricha)
Q60300956	Metabolic bone disease risk factors strongly contributing to long bone and rib fractures during early infancy: A population register study
Q87974587	Metabolic bone disease screening practices among U.S. neonatologists
Q34775379	Metabolic bone disease secondary to renal and intestinal disorders
Q69804970	Metabolic bone disease with and without osteomalacia after intestinal bypass surgery: a bone histomorphometric study
Q37807582	Metabolic bone disease: Atypical femoral fractures
Q36700987	Metabolic bone disease: Newer perspectives
Q68345585	Metabolic bone disease: Problems of terminology
Q45332955	Metabolic bone disease: a continued challenge in extremely low birth weight infants.
Q30842615	Metabolic bone disease: a review and update.
Q39648913	Metabolic bone disease: a review.
Q35105336	Metabolic bone disease: an update
Q46275655	Metabolic bone disease: bone development and remodeling
Q46275659	Metabolic bone disease: calcification and matrix vesicle
Q40305431	Metabolic bone disease: osteoporosis and osteomalacia
Q67022705	Metastatic Bone Disease
Q39388348	Metastatic Bone Disease: Future Directions
Q67022750	Metastatic bone disease
Q72399314	Metastatic bone disease
Q77693716	Metastatic bone disease
Q74062467	Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases
Q41194466	Metastatic bone disease and the role of bisphosphonates.
Q34686881	Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates
Q35668817	Metastatic bone disease and tumour-induced hypercalcaemia: treatment options
Q51295142	Metastatic bone disease as seen in our clinical practice--experience at a tertiary care cancer center in Pakistan.
Q53970044	Metastatic bone disease developing in patients with potentially curable breast cancer.
Q79006740	Metastatic bone disease from a malignant tumor of the nasopharynx. A case report
Q92858719	Metastatic bone disease from an occult renal primary
Q39361467	Metastatic bone disease from breast cancer: a review of minimally invasive techniques for diagnosis and treatment
Q69651459	Metastatic bone disease from occult carcinoma: a profile
Q34360985	Metastatic bone disease in breast cancer: the patient's perspective
Q38095288	Metastatic bone disease in the era of bone-targeted therapy: clinical impact
Q35188466	Metastatic bone disease of the humerus
Q89251082	Metastatic bone disease of the pelvis and extremities: rationalizing orthopaedic treatment
Q68128257	Metastatic bone disease of the pelvis and femur
Q74296053	Metastatic bone disease presenting as trochanteric bursitis
Q45761973	Metastatic bone disease secondary to breast cancer: an all too common cause of low back pain
Q30248588	Metastatic bone disease: A review of survival, prognostic factors and outcomes following surgical treatment of the appendicular skeleton
Q36934275	Metastatic bone disease: Have we improved after a decade of guidelines?
Q92772115	Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management
Q36836803	Metastatic bone disease: a 36-year single centre trend-analysis of patients admitted to a tertiary orthopaedic surgical department.
Q45757711	Metastatic bone disease: a review of various concepts and report of a case
Q36089484	Metastatic bone disease: clinical and therapeutic aspects
Q28202792	Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Q35806133	Metastatic bone disease: current concepts of clinicopathophysiology and modern surgical treatment
Q37504436	Metastatic bone disease: diagnosis, evaluation, and treatment
Q84101517	Metastatic bone disease: diagnosis, evaluation, and treatment
Q37677678	Metastatic bone disease: evaluation by functional imaging in correlation with morphologic modalities.
Q73829608	Metastatic bone disease: evaluation, clinicopathologic features, biopsy, fracture risk, nonsurgical treatment, and supportive management
Q36120057	Metastatic bone disease: general principles, pathophysiology, evaluation, and biopsy
Q80386581	Metastatic bone disease: pathogenesis and new strategies for treatment
Q68130049	Metastatic bone disease: philosophy of treatment
Q54228181	Metastatic bone disease: role of bisphosphonates.
Q34217531	Metastatic bone disease: role of transcription factors and future targets
Q33970362	Metastatic bone disease: the requirement for improvement in a multidisciplinary approach
Q40500208	Method to quantify uptake of radiophosphorus in therapy of metastatic bone disease using99Tcmradiophosphate
Q37871863	Methotrexate toxicity in growing long bones of young rats: a model for studying cancer chemotherapy-induced bone growth defects in children
Q67752923	Methoxypropriocin in the treatment of degenerative bone disease (comparative studies)
Q89471249	Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome
Q26770478	MicroRNAs in multiple myeloma and related bone disease
Q58613918	Mineral and Bone Disease in Kidney Transplant Recipients
Q41840864	Mineral and bone disease in african renal failure patients
Q42863013	Mineral and bone disease in black african hemodialysis patients.
Q36734438	Mineral and bone disease in black african hemodialysis patients: a report from senegal
Q42863011	Mineral and bone disease in hemodialysis patients
Q43125953	Mineral and bone disease pattern in elderly haemodialysis patients.
Q99413086	Mineral bone disease in autosomal dominant polycystic kidney disease
Q34186438	Mineral bone disease in maintenance hemodialysis patients: Association with morbidity and mortality
Q37065058	Mineral metabolism and bone disease after bariatric surgery and ways to optimize bone health
Q40882470	Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis.
Q57643994	Minocycline-induced black bone disease encountered during total knee arthroplasty
Q99199393	Mirels Scores in Patients Undergoing Prophylactic Stabilization for Femoral Metastatic Bone Disease in the Veterans Administration Healthcare System
Q38491226	Modern Palliative Treatments for Metastatic Bone Disease: Awareness of Advantages, Disadvantages, and Guidance
Q104516515	Modified Serum ALP Values and Timing of Apparition of Knee Epiphyseal Ossification Centers in Preterm Infants with Cholestasis and Risk of Concomitant Metabolic Bone Disease of Prematurity
Q48526783	Modular megaprosthesis in metastatic bone disease of the femur
Q39469248	Modular prostheses in metastatic bone disease of the proximal femur
Q34502398	Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders
Q91579685	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Q70935947	Monocytic leukaemia associated with myeloid metaplasia, resembling metastatic bone disease
Q92257060	Morbidity and Mortality: A Case Report of Metastatic Bone Disease
Q81318588	Mouse models and the RANKL/OPG axis in myeloma bone disease
Q53186388	Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer.
Q40195683	Multicentric Disappearing Bone Disease treated with Arthroplasty
Q30452491	Multicystic bone disease (Gorham-Stout syndrome) in a spider monkey (Ateles geoffroyi ).
Q45886364	Multifactorial aetiology for bone disease in patients with haemophilia
Q69936492	Multifactorial low remodeling bone disease during cyclic total parenteral nutrition
Q91813273	Multimodal therapy in urachal carcinoma with oligometastatic bone disease
Q42690512	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features
Q36508453	Multiple Brown Tumors Caused by a Parathyroid Adenoma Mimicking Metastatic Bone Disease from Giant Cell Tumor
Q98201530	Multiple Myeloma Associated Bone Disease
Q87895658	Multiple Myeloma with Advanced Bone Disease and Low Tumor Burden - Different Clinical Presentation but Similar Outcome after Bortezomib-Based Therapy and Radiotherapy
Q96770197	Multiple Spontaneous Osteoporotic Fractures Mimicking Metastatic Bone Disease
Q50708282	Multiple brown tumors in primary hyperparathyroidism caused by an adenoma mimicking metastatic bone disease with false positive results on computed tomography and Tc-99m sestamibi imaging: MR findings.
Q33953955	Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.
Q36569101	Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Q34038854	Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics
Q71727010	Multiple myeloma: optimal use of salmon calcitonin in the management of myeloma osteoclastic bone disease
Q37607852	Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary
Q34359471	Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation
Q72938852	Muscle weakness simulating myopathy in metabolic bone disease
Q72613139	Muscular disorders of metabolic bone disease
Q44266800	Myelofibrosis presenting as hypermetabolic bone disease by radionuclide imaging in a patient with asplenia
Q57794000	Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
Q36490144	Myeloma and bone disease: "the dangerous tango".
Q60482582	Myeloma bone disease
Q80388420	Myeloma bone disease
Q81271143	Myeloma bone disease
Q77312705	Myeloma bone disease
Q36818075	Myeloma bone disease and proteasome inhibition therapies.
Q36517647	Myeloma bone disease and treatment options
Q55209965	Myeloma bone disease: Pathophysiology and management.
Q38920028	Myeloma bone disease: Progress in pathogenesis
Q91555973	Myeloma bone disease: from biology findings to treatment approaches
Q38673703	Myeloma bone disease: pathogenesis and treatment
Q81136632	Myeloma bone disease: pathogenesis and treatment
Q38246241	Myeloma bone disease: pathogenesis, current treatments and future targets
Q36501851	Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
Q36146493	Myeloma bone disease: pathophysiology and management.
Q37415064	Myeloma bone disease: recent advances in biology, diagnosis, and treatment
Q49843807	Myelosuppression, Bone Disease, and Acute Renal Failure: Evidence-Based Recommendations for Oncologic Emergencies.
Q34700910	Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome).
Q72428740	Mönckeberg's arteriosclerosis and metabolic bone disease
Q27027330	Nanostructured biomaterials for tissue engineered bone tissue reconstruction
Q36975264	Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration.
Q38198892	Nasu-Hakola disease as suspected cause for bone disease and dementia.
Q40572257	Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.
Q33491284	Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
Q35034474	Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey
Q34109952	Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Q35080143	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey
Q44251471	Navicular bone disease: a comparative histomorphometric study
Q41596512	Navicular bone disease: results of treatment using egg-bar shoeing technique
Q91892394	Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice
Q70215544	Neonatal rickets: metabolic bone disease of prematurity
Q34936324	Nephrolithiasis-associated bone disease: pathogenesis and treatment options
Q69787680	Neutron activation analysis of a hand-a method of monitoring progressive bone disease
Q79578013	Nevus comedonicus syndrome in a woman with Paget bone disease and breast cancer: a mere coincidence?
Q50323850	New agents in the Treatment of Myeloma Bone Disease
Q53860447	New approach to the treatment of bone disease with fluoride
Q71504244	New approach to the treatment of bone disease with fluoride. Discussion
Q36968968	New aspects of treatment of renal bone disease in dialysis patients.
Q67921451	New biochemical marker for bone disease: is it a breakthrough?
Q91320848	New diagnostic modalities and emerging treatments for neonatal bone disease
Q35591086	New insights into the pathophysiology and management of bone disease in multiple myeloma
Q66832714	New metabolic bone disease research unit
Q81241026	New prospects for the management of renal bone disease
Q92949000	New role for adipocytes in tumour-associated bone disease
Q68514374	Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia
Q39422063	No superior surgical treatment for secondary osteochondral defects of the talus
Q39401706	No superior treatment for primary osteochondral defects of the talus
Q99359025	Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Q64274109	Non-Viral Delivery System and Targeted Bone Disease Therapy
Q57226447	Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?
Q68174231	Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients
Q38176598	Non-muscle involvement in late-onset glycogenosis II.
Q70599139	Non-protein-bound hydroxyproline in plasma in renal bone disease
Q70995246	Noninflammatory bone disease
Q69587424	Normal Fluoride 18 Bone Scans in Metastatic Bone Disease
Q71767821	Normal linear growth in hypophosphataemic bone disease
Q55117232	Nosology and classification of genetic skeletal disorders: 2010 revision.
Q33840195	Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model
Q92157976	Novel functions of the primary cilium in bone disease and cancer
Q82282522	Novel targets for myeloma bone disease
Q80386544	Nutrition and bone disease
Q40530052	Nutrition and bone disease in the dog and cat.
Q70068536	Nutrition and metabolic bone disease in old age
Q71217609	Nutrition and metabolic bone disease in the elderly
Q38521471	Nutrition, bone disease and alcoholic cirrhosis
Q68227802	Nutrition-related bone disease
Q52709954	Nutritional Metabolic Bone Disease in Juvenile Veiled Chameleons (Chamaeleo calyptratus) and Its Prevention
Q35578707	Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients
Q41088278	Nutritional aspects of metabolic bone disease in the newborn
Q37170632	Nutritional bone disease in Indian population.
Q72297760	Nutritional bone disease in non-domesticated mammals
Q39836768	Nutritional factors of lameness and metabolic bone disease in cattle
Q59216754	O322 Bone disease and HIV – together for the long term
Q74534907	OBSTRUCTIVE jaundice and nutritional bone disease
Q91507128	OSTEODENSITOMETRY AND TOMOGRAPHIC FINDINGS IN FOUR CAPTIVE GIANT SOUTH AMERICAN TURTLES (PODOCNEMIS EXPANSA) WITH METABOLIC BONE DISEASE
Q28083419	Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep
Q50088084	Occult metabolic bone disease in chronic pancreatitis
Q39487473	Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial
Q39242994	Oligometastatic bone disease. Can limited metastatic bone disease be cured? Is there room for local ablative treatments?
Q64228409	One Disease, Many Genes: Implications for the Treatment of Osteopetroses
Q36996265	One in three: congenital bent bone disease and intermittent hyperthermia in three siblings with stuve-wiedemann syndrome
Q43592303	Ophthalmologic symptoms in atypical marble bone disease (Albers-Schönberg)
Q52665445	Opportunistic screening for bone disease using abdominal CT scans obtained for other reasons in newly diagnosed IBD patients.
Q61623301	Optimal and receding horizon control of tumor growth in myeloma bone disease
Q37100364	Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease
Q83800946	Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility
Q69839456	Oral findings in patients with autosomal dominant hypophosphatemic bone disease and X-linked hypophosphatemia: further evidence that they are different diseases
Q44865252	Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
Q45236667	Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
Q36694734	Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
Q71886050	Oral presentation of minocycline-induced black bone disease
Q36084837	Orthopaedic applications of nanoparticle-based stem cell therapies
Q59340080	Orthopaedic challenges for mucopolysaccharidoses
Q37990280	Orthopaedic manifestations of sickle-cell disease.
Q97536209	Orthopedic Surgical Treatment and Perioperative Complications in Multiple Myeloma Bone Disease: Analysis of a Series (2009-2018)
Q72199309	Osseous radiologic manifestations associated with anemia in children
Q41308717	Osteitis Deformans (Paget's Bone Disease) with Chronic Eczema.
Q78609939	Osteitis fibrosa localisata (brown tumor or osteoclastoma) and aseptic bone necrosis as a cause for sesamoid bone disease of the first metatarsal; case report
Q69630561	Osteoarticular manifestations of scleroderma. Apropos of 14 cases
Q44540276	Osteoarticular manifestations of sickle cell disease
Q30416347	Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease
Q34720969	Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease
Q90786412	Osteoblast suppression in multiple myeloma bone disease
Q70385216	Osteocalcin and bone morphometric parameters in adults without bone disease
Q72898115	Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD
Q68097404	Osteocalcin: a potential marker of metastatic bone disease and response to treatment
Q86693724	Osteoclast activation and sickle bone disease
Q80720667	Osteoclastoma associated with generalized bone disease
Q39062996	Osteogenic Differentiation in Healthy and Pathological Conditions
Q71378940	Osteoid in bones of elderly patients without bone disease
Q95780695	Osteoid in metabolic bone disease
Q26828486	Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts
Q70055577	Osteolytic Paget's bone disease in a young man. Rapid healing with human calcitonin therapy
Q37036650	Osteomalacia and Hyperparathyroid Bone Disease in Patients with Nephrotic Syndrome
Q69026307	Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy
Q39595757	Osteomalacia and bone disease arising from aluminum
Q46289730	Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate
Q37394305	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Q65474528	Osteopathic Manipulative Treatment for Post-Operative Nausea and Vomiting
Q64187200	Osteopathic Procedure on Pain in Palliative Care
Q66400289	Osteopathic Support Evaluation of Fibromyalgia Patients
Q65340778	Osteopathic Treatment in Patients With Low Back Pain: Stabilometry
Q64652309	Osteopathy and Obstructive Sleep Apnea Syndrome
Q65370408	Osteopathy and Obstructive Sleep Apnea Syndrome II
Q71671443	Osteopenic bone disease
Q73074705	Osteopetrosis (Albers-Schönberg disease; marble bone disease)
Q41161996	Osteopetrosis (Marble Bone Disease): A Rare Disease in Children
Q40014412	Osteopetrosis (Marble bone disease) of the temporal bone
Q35255015	Osteopetrosis (marble bone disease); clinical and pathological review.
Q87509285	Osteopoikilosis: A Benign Condition With the Appearance of Metastatic Bone Disease
Q64076938	Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2
Q66947273	Osteoporosis- more than a bone disease (author's transl)
Q68722710	Osteoporosis: bone disease in the elderly
Q66881501	Osteoporosis: dealing with a crippling bone disease of the elderly
Q68770181	Osteoporotic bone disease in the pyridoxine-deficient rat
Q77337118	Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Q61978441	Osteoprotegerin: a new therapeutic agent for the treatment of bone disease
Q72252377	Osteosynthesis in marble bone disease Albers-Schönberg
Q47225475	Outcomes of standardised approach to metabolic bone disease of prematurity
Q37170245	Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets
Q83945046	Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets
Q50848634	Overexpression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis.
Q35553301	Overview of renal bone disease: Causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach
Q24546181	Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease
Q67267884	Oxalosis-induced bone disease: a complication of transplantation and prolonged survival in primary hyperoxaluria
Q93582323	PARATHYROID GLANDS AND METABOLIC BONE DISEASE
Q57026125	PET-MRI for the Study of Metabolic Bone Disease
Q49632954	PREVALENCE OF OSTEOPOROSIS AND HYPOVITAMINOSIS D AT SIRIRAJ METABOLIC BONE DISEASE CLINIC.
Q90980406	PROMIS® scores in operative metastatic bone disease patients: A multicenter, prospective study
Q74537055	PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease
Q39137073	PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression.
Q76505155	PULMONARY, HEPATIC, RENAL, MYOCARDIAL AND BONE DISEASE: A NEW PATHOLOGIC ENTITY?
Q90822817	Paediatric Metabolic Bone Disease: A Lifetime Ahead
Q68077374	Paget bone disease and heredity: a case report
Q52989823	Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.
Q41507464	Paget bone disease involving young adults in 3 generations of a Korean family.
Q71223718	Paget bone disease: radiologic documentation of healing with human calcitonin therapy
Q41615899	Paget's bone disease and virus (author's transl)
Q89248631	Paget's bone disease is not always the culprit
Q39369200	Paget's bone disease treated with diphosphonate and calcitonin
Q69486264	Paget's bone disease, anaemia and vitiligo: a case report
Q54249446	Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin.
Q59629414	Pain Control with Zoledronic Acid in Patients with Breast Cancer and Metastatic Bone Disease
Q59137619	Pain Management in Metastatic Bone Disease: A Literature Review
Q24803367	Paleopathological diagnosis and interpretation. Bone disease in ancient human populations
Q47938556	Palliation of Extensive Metastatic Bone Disease With 223Ra-Dichloride α-Particle Therapy in a Patient With Malignant Hereditary Paraganglioma-Pheochromocytoma Syndrome With SDHB Mutation
Q71353067	Palliative effect of cyproterone acetate in carcinoma of the prostate with widespread metastatic bone disease
Q36657098	Palliative surgery of metastatic bone disease: A review of 83 cases
Q72359295	Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
Q34756566	Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Q67934101	Pancreatic carcinoid with extensive osteolytic bone disease
Q35568480	Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK.
Q60174371	Paradise lost: Evidence for a devastating metabolic bone disease in an insular Pleistocene deer
Q97532549	Paraspinal soft tissue masses in a patient with a metabolic bone disease
Q58634097	Parathyroid Hormone (PTH) Assays and Applications to Bone Disease: Overview on Methodology
Q58634182	Parathyroid Hormone (PTH) Assays and Applications to Bone Disease: Overview on Methodology
Q85665971	Parathyroid hormone as a marker for metabolic bone disease of prematurity
Q87979873	Parathyroid hormone as a marker for metabolic bone disease of prematurity
Q93559130	Parathyroid hormone in aluminum bone disease
Q68724073	Parathyroid hormone in aluminum bone disease: a comparison of parathyroid hormone assays
Q43935622	Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients
Q72164989	Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis
Q83874341	Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease
Q91327677	Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patiente. Far beyond mineral bone disease regulation
Q69588957	Partial body neutron activation analysis in vivo: a new approach to the investigation of metabolic bone disease
Q84884081	Patellar fracture: atypical presentation of parathyroid bone disease
Q80157174	Pathogenesis of bone disease in cystic fibrosis: the role of bone size and sarcopenia
Q47734632	Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Q99555716	Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2
Q73391479	Pathologic changes, mechanisms and diagnosis in renal bone disease
Q80974012	Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Q74696795	Pathologic fractures due to metastatic bone disease
Q68695140	Pathological fractures in metabolic bone disease
Q39628918	Pathology of disappearing bone disease: a case report with immunohistochemical study.
Q36201053	Pathophysiology and diagnosis of third carpal bone disease in horses: a review
Q41348087	Pathophysiology and management of bone disease in multiple myeloma
Q37856334	Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions.
Q71139430	Pathophysiology and treatment of uremic bone disease
Q38706122	Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine
Q67952021	Pathophysiology of aluminum-induced bone disease
Q44987912	Patient Education. Bone disease: preparing for your parathyroidectomy
Q84190338	Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study
Q47224824	Patient survival following joint replacement due to metastatic bone disease - comparison of overall patient and prostheses survival between cohorts treated in two different time-periods
Q69761134	Pattern of bone disease in maintenance haemodialysis patients in Malaysia
Q67277221	Patterns of bone disease in maintenance haemodialysis patients in Singapore
Q92862671	Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Q73514630	Patterns of metastatic bone disease and their implications
Q89197536	Pediatric Bone
Q46652817	Pediatric bone disease: a decade of discovery
Q83635825	Pediatric endocrinology reviews. Diabetes, nutrition, metabolism. Bone disease and endocrine complications in thalassaemia. Forward
Q87142441	Pediatric intestinal failure: Predictors of metabolic bone disease
Q39940334	Peripatetic intravenous service for metabolic bone disease: case study in patient centred-care for new NHS.
Q92475977	Permian metabolic bone disease revealed by microCT: Paget's disease-like pathology in vertebrae of an early amniote
Q81385312	Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy
Q74532374	Persisting aluminium-related bone disease after cadaveric renal transplantation
Q35868347	Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model
Q101559514	Pharmacologic Management of Metastatic Bone Disease
Q33729548	Pharmacological management of osteogenesis
Q35679883	Phosphate and Klotho
Q24234036	Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Q24244049	Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Q92368089	Physical function and pain intensity in patients with metastatic bone disease
Q88392264	Pinpointing a Factor in Myeloma Bone Disease
Q93127309	Plasma Phosphatase and Bone Disease
Q73513762	Polycystic bone disease
Q78157854	Polycystic bone disease: A new, autosomal dominant disorder
Q43623605	Polymorphism of the vitamin D receptor and bone disease after renal transplantation
Q43440903	Polyphosphate bone scanning of non-malignant bone disease in children
Q28391758	Population ancestry and genetic risk for diabetes and kidney, cardiovascular, and bone disease: modifiable environmental factors may produce the cures
Q68410688	Possibility for surgical management of femur shaft fracture in osteopetrosis (marble bone disease, Albers-Schönberg disease)
Q88731907	Possible prostate cancer in northern Peru: Differential diagnosis, vascular anatomy, and molecular signaling in the paleopathology of metastatic bone disease
Q64910535	Post-gastrectomy bone disease undiagnosed for forty years.
Q41082297	Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton
Q70933687	Postabsorptive Urinary Hydroxyproline Test in Patients With Metastatic Bone Disease From Breast Cancer
Q36855529	Postnatal Changes in Humerus Cortical Bone Thickness Reflect the Development of Metabolic Bone Disease in Preterm Infants
Q41273646	Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs
Q43675904	Posttransplant bone disease: a case illustrating dramatic improvements in bone density with vitamin D replacement therapy
Q73383291	Posttransplant bone disease: evidence for a high bone resorption state
Q81563751	Posttransplantation bone disease
Q91600305	Potential applications for rhIGF-I: Bone disease and IGFI
Q36455114	Potential for Early Fracture Risk Assessment in Patients with Metastatic Bone Disease using Parametric Response Mapping of CT Images
Q59713041	Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease
Q64228563	Prediction of survival after surgical management of femoral metastatic bone disease - A comparison of prognostic models
Q35770778	Predictors of bone disease in Egyptian prepubertal children with β-thalassaemia major
Q73466032	Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease
Q42277957	Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery
Q81310583	President's welcome. VII International Meeting on Cancer Induced Bone Disease
Q70369582	Pretreatment of chronic suppurative bone disease before definitive surgery
Q43511328	Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation.
Q73181433	Prevalence and incidence of alveolar bone disease in men
Q43026414	Prevalence and pattern of renal bone disease in end stage renal disease patients in Ile-Ife, Nigeria.
Q93370920	Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula
Q57005320	Prevalence of bone disease in patients on home parenteral nutrition
Q84383349	Prevalence of metabolic bone disease among chronic rhinosinusitis patients treated with oral glucocorticoids
Q37567402	Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis
Q57463395	Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models
Q41896064	Preventing bone disease requires diligent management in patients with renal failure
Q57227228	Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3
Q90833341	Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
Q54172407	Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation.
Q34302383	Prevention of metabolic bone disease in the pre-end-stage renal disease setting
Q69276646	Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3
Q31842904	Prevention of uremic bone disease using calcimimetic compounds.
Q96124393	Primary Sjogren's syndrome manifesting with distal renal tubular acidosis and severe metabolic bone disease
Q57826362	Primary biliary cholangitis and bone disease
Q72371445	Primary biliary cirrhosis and bone disease
Q46151136	Primary hydatidosis of the chest wall. Report of 5 cases
Q90981372	Primary hyperparathyroid bone disease
Q44200865	Primary hyperparathyroidism caused by a mediastinal adenoma with intermittent hypercalcemia and severe bone disease
Q74015646	Primary hyperparathyroidism with metabolic bone disease
Q71862121	Privational and malabsorption metabolic bone disease: plasma vitamin D metabolite concentrations and their relationship to quantitative bone histology
Q64910852	Probiotics in Extraintestinal Diseases: Current Trends and New Directions.
Q81958643	Proceedings and abstracts of the VII International Meeting on Cancer Induced Bone Disease, June 2008, Edinburgh, UK
Q79254877	Proceedings from the Association of Bone and Joint Surgeons Symposium on Metastatic Bone Disease, November 2002
Q80707941	Proceedings of the 18th Annual Meeting of the Japanese Society for Kidney Bone Disease, February 24, 2007, Tokyo, Japan
Q36585097	Proceedings: A simplified approach to metabolic bone disease
Q84654680	Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Q90786422	Prognostic and risk factors in patients with metastatic bone disease of an upper extremity
Q43007055	Prognostic factors for skeletal complications from metastatic bone disease in breast cancer
Q68003748	Prognostic indicators of metastatic bone disease in human breast cancer
Q40407387	Prognostic value of biochemical variables for survival after surgery for metastatic bone disease of the extremities
Q72428973	Progression of bone disease without deterioration of hematological parameters in a child with Gaucher disease during low-dose glucocerebrosidase therapy
Q83487638	Prophylactic stabilization of proximal femoral metastatic bone disease: reconstruction intramedullary nail fracture
Q71354010	Prospective evaluation of metabolic bone disease after jejunoileal bypass
Q48910291	Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers.
Q70762873	Prostaglandin E2 administered by subcutaneous pellets causes local inflammation and systemic bone loss: a model for inflammation-induced bone disease
Q39470975	Prosthesis for the treatment of metastatic bone disease of the hip: effects of radiotherapy.
Q33990050	Proximal femoral replacements for metastatic bone disease: financial implications for sarcoma units.
Q78850359	Pseudohyperparathyroidism. Description and pathogenic interpretation of a case of metabolic bone disease, hypophosphatemia and hypercalciuria
Q53728990	Pyknodysostosis (apropos of 3 cases)
Q67296356	Quantification of skeletal Tc-99m labeled phosphates to defect metabolic bone disease
Q69782036	Quantitative Histological Studies on the Pathogenesis of Uremic Bone Disease*
Q44064323	Quantitative assessment of metabolic bone disease in rat models by dual tracer method
Q39428551	Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate
Q67291370	Quantitative radionuclide scanning in metabolic bone disease
Q71581193	Quantitative study of tunneling and hook resorption in metabolic bone disease
Q77081877	RADIAL RATE OF OSTEON CLOSURE: ITS APPLICATION IN THE STUDY OF BONE FORMATION IN METABOLIC BONE DISEASE
Q78503340	RADIOLOGICAL ASPECTS OF LEUKEMIC BONE DISEASE AND ITS MODIFICATIONS IN THE COURSE OF THERAPY
Q28287091	RANKL-RANK signaling in osteoclastogenesis and bone disease
Q91202294	REVIEW ON BONE DISEASE (OSTEOPOROSIS) IN DIABETES MELLITUS
Q73292242	Radial Bone Mineral Density in Hemodialysis Patients with Adynamic Bone Disease
Q73771098	Radiating spicules, a nonspecific sign of bone disease
Q79001001	Radioactive phosphorus for carcinoma of the breast with diffuse metastatic bone disease
Q78383743	Radiocalcium studies of bone formation rate in human metabolic bone disease
Q64072363	Radiographic and histological evidence of metabolic bone disease in gliding leaf frogs ()
Q84313086	Radiographic diagnosis of metabolic bone disease in captive bred mountain chicken frogs (Leptodactylus fallax)
Q72806700	Radiographic manifestations of aluminum-induced bone disease
Q67914721	Radiolabelled granulocytes in inflammatory bone disease
Q93731141	Radiologic diagnosis of metabolic bone disease
Q70028271	Radiological assessment of aluminium-related bone disease
Q69544218	Radiological changes with ageing in relation to bone disease and arthritis
Q83328394	Radiological diagnosis of bone disease
Q69961441	Radiological evaluation of temporal bone disease: high-resolution computed tomography versus conventional X-ray diagnosis
Q39923570	Radiological patterns of bone disease associated with renal glomerular failure in adults
Q58086821	Radiological/Pathological Correlations in Uremic Bone Disease
Q52110415	Radiology case of the month. Sclerotic bone disease in an 8-year-old dwarf. Pycnodysostosis.
Q77170917	Radiology of metabolic bone disease: osteoporosis
Q71206734	Radiology of metabolic bone disease: workshop report
Q37752373	Radiotherapy for metastatic bone disease: current standards and future prospectus
Q36372417	Radiotherapy, Bisphosphonates and Surgical Stabilization of Complete or Impending Pathologic Fractures in Patients with Metastatic Bone Disease
Q33405335	Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
Q37639913	Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases
Q39208355	Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model
Q35889739	Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy
Q77549650	Rapid changes in the scintigraphic pattern in Tc-99m DPD whole-body scanning in metabolic bone disease
Q68015181	Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine
Q28066355	Rapid phenotyping of knockout mice to identify genetic determinants of bone strength
Q91674947	Rare GBA1 genotype associated with severe bone disease in Gaucher disease type 1
Q58591167	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain
Q81228185	Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease
Q82530327	Re.: Nephrolithiasis-associated bone disease: pathogenesis and treatment options
Q80033947	Re: Chronic lymphocytic leukemia resembling metastatic bone disease
Q37884373	Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets
Q71000573	Recognition of metastatic bone disease in cancer of the breast by computed tomography
Q35451868	Recommendations for evaluation and management of bone disease in HIV.
Q89593362	Reconstruction of the Shoulder and Humerus in Metastatic Bone Disease
Q46302062	Recovery from metabolic bone disease in a girl with vitamin D deficiency rickets associated with primary hyperparathyroidism
Q70430199	Regional measurement of bone calcium accretion rate and exchangeable pool with a whole-body counter: method and studies in subjects without bone disease
Q37884121	Regulation of bone by the adaptive immune system in arthritis
Q52584355	Regulation of breast cancer induced bone disease by cancer-specific IKKβ.
Q71391789	Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma
Q57564200	Relationship between Vitamin A and Bone Disease in Chronic Renal Failure
Q51023673	Relationship between bone metabolism and plasma cytokine levels in patients at risk of post-transplantation bone disease after bone marrow transplantation.
Q47989342	Relationship between metabolic bone disease and bone mineral density measured by dual-energy X-ray absorptiometry in the green iguana (Iguana iguana).
Q46825347	Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation.
Q79595290	Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma
Q74296343	Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
Q52983002	Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Q71891407	Renal Bone Disease, Parathyroid Hormone and Vitamin D. Proceedings of ISN satellite symposium. Seville, Spain, July 7-11, 1995
Q41676920	Renal Excretion Simulating Bone Disease on Bone Scans???a Technique for Solving this Problem
Q67371492	Renal bone disease
Q69882836	Renal bone disease
Q70194761	Renal bone disease
Q37953234	Renal bone disease 1990: an unmet challenge for the nephrologist
Q43709744	Renal bone disease among patients with ESRD.
Q71163832	Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study
Q68273959	Renal bone disease in chronic uremic rats
Q67824278	Renal bone disease in patients on haemodialysis: biochemical and radiological assessment
Q72851046	Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital
Q36928635	Renal bone disease in pediatric patients receiving treatment with maintenance peritoneal dialysis
Q78002298	Renal bone disease in peritoneal dialysis
Q35157959	Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry
Q33816206	Renal bone disease: radiological investigation.
Q37688127	Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study
Q80403161	Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease
Q35171452	Renal tubular acidosis due to Wilson's disease presenting as metabolic bone disease
Q79124649	Renal tubular hyperchloremic acidosis with bone disease: a case report
Q68862523	Renal ultrasound in metabolic bone disease
Q93537314	Reply to Letter to the Editor: Unexplained Fractures: Child Abuse or Bone Disease: A Systematic Review
Q45999829	Reply to Letter to the Editor: Unexplained Fractures: Child Abuse or Bone Disease: A Systematic Review.
Q92381685	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Q70225315	Resolution of hypercalcemia and aluminum bone disease after renal transplantation
Q34661032	Response of Gaucher bone disease to enzyme replacement therapy
Q88397355	Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease
Q57772100	Response to ‘Adynamic Bone Disease and MICS’
Q60678641	Results From a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease From Italian Sites
Q59126536	Rethinking Bone Disease in Kidney Disease
Q39169395	Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy
Q57221775	Reversal of adynamic bone disease by lowering of dialysate calcium
Q46296614	Reversal of aluminum-related bone disease after renal transplantation
Q57227250	Reversal of aluminum-related bone disease after substituting calcium carbonate for aluminum hydroxide
Q51070632	Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
Q35880384	Review article: bone disease in inflammatory bowel disease
Q36095381	Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials
Q37888361	Review: most interventions for preventing bone disease in chronic renal failure improved biochemical outcomes
Q83134229	Rheumatic manifestations of genetic hemochromatosis
Q80940205	Rheumatologic manifestations of hypothyroidism
Q30248491	Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease
Q58598164	Risk factors analysis and prevention of metabolic bone disease of prematurity
Q50132808	Risk factors and biochemical markers in metabolic bone disease of premature newborns
Q85961009	Risk factors for developing mineral bone disease in phenylketonuric patients
Q60697067	Risk factors for metabolic bone disease in Crohnʼs disease patients
Q38661939	Risk factors of metabolic bone disease of prematurity
Q59313369	Risk of Metabolic Bone Disease is Increased Both during and after Weaning off Parenteral Nutrition in Pediatric Intestinal Failure
Q67909470	Risk of adynamic bone disease in dialyzed patients
Q43691240	Risk of bone disease as a result of fluoride intake in chronic renal insufficiency
Q90567814	Role of APD-Ribosylation in Bone Health and Disease
Q37678085	Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Q59539917	Role of Dietary Phosphorus and Degree of Uremia in the Development of Renal Bone Disease in Rats
Q58566593	Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
Q37344527	Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection
Q55254641	Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.
Q40778071	Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy.
Q90422031	Role of angiocrine signals in bone development, homeostasis and disease
Q38334877	Role of apoptosis in pathogenesis and treatment of bone-related diseases.
Q73444978	Role of osteoclastic dysfunction in the development of renal bone disease
Q26992195	Role of osteocytes in multiple myeloma bone disease
Q77588187	Role of pamidronate disodium in the treatment of metastatic bone disease
Q34898865	Runx2-Smad signaling impacts the progression of tumor-induced bone disease
Q81240021	SAPHO syndrome masquerading as metastatic bone disease
Q78398403	SECONDARY MARBLE BONE DISEASE: GENERALISED OSTEOSCLEROSIS AND MYELOFIBROSIS IN CARCINOMA OF PROSTATE WITH A CASE REPORT
Q36372598	SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice
Q37327588	SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Q76569854	STUDIES OF BONE DISEASE USING CALCIUM-47
Q62618686	SaO030FIVE-YEAR MORTALITY AND HOSPITALIZATION RISK ASSOCIATED WITH CHRONIC KIDNEY DISEASE MINERAL BONE DISEASE (CKD-MBD)
Q69044754	Sacro-iliac involvement in sarcoidosis. Apropos of a case
Q44736572	Sarcoidosis mimicking metastatic bone disease in head and neck cancer
Q68764689	Sarcomatous degeneration in Paget's bone disease
Q49223007	Scaffolds for the repair of bone defects in clinical studies: a systematic review
Q92120184	Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment
Q67827727	Scintigraphy in uremic bone disease
Q53137198	Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis.
Q100696013	Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children
Q89817653	Screening for Metabolic Bone Disease of prematurity
Q73071337	Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients
Q42253688	Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy
Q37719717	Segmental bone defects: from cellular and molecular pathways to the development of novel biological treatments
Q66959687	Semi-quantitative interpretation of the bone scan in metabolic bone disease: definition and validation of the metabolic index
Q64250359	Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease-A Novel Target for Treatment
Q61781913	Serine Proteases in Bone Disease
Q46057559	Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
Q37627936	Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases.
Q72551634	Serum aluminium measurements in renal bone disease
Q52919769	Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Q34062894	Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
Q37190115	Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
Q44138678	Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Q79084045	Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma
Q82833783	Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis
Q70583295	Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry
Q69868501	Serum osteocalcin concentrations in children with metabolic bone disease
Q80085809	Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease
Q57374932	Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease
Q71742885	Serum total hydroxyproline assay: effects of age, sex and Paget's bone disease
Q46535491	Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols
Q40840017	Seven-year follow-up of vanishing bone disease in a 14-year-old girl
Q35020700	Severe bone disease and low bone mineral density after juvenile renal failure
Q100989836	Severe bone disease caused by primary hyperparathyroidism: a case report and review of the literature
Q84142364	Severe bone disease with bilateral femur fracture in a young woman after gastrectomy for gastric polyposis with SMAD4 mutation
Q78563161	Severe metabolic bone disease as a long-term complication of obesity surgery
Q33590554	Severe metabolic bone disease in pregnancy mimicking malignancy
Q83807035	Short- and Long-term HRV Measurements After Osteopathic Myofascial Thoracic Manipulations
Q33302031	Sickle cell bone disease: response to vitamin D and calcium
Q64122338	Side effects of drugs for osteoporosis and metastatic bone disease
Q80366101	Significance of minimodeling in dialysis patients with adynamic bone disease
Q54437684	Simian bone disease: unrecognized rickets in rhesus monkeys
Q93757957	Skeletal Renewal and Metabolic Bone Disease
Q53566751	Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis?
Q79984770	Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
Q66847886	Skeletal remodeling physiology and its relation to metabolic bone disease
Q68586981	Skeletal renewal and metabolic bone disease
Q89830100	Society for Pediatric Radiology (SPR) Child Abuse Committee response regarding Miller, Stolfi and Ayoub's flawed theories about child abuse and metabolic bone disease
Q57227902	Sodium fluoride treatment of bone disease in multiple myeloma
Q39827231	Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
Q40003850	Some aspects of metabolic bone disease related to rheumatology
Q79386654	Some curable types of metabolic bone disease
Q40725264	Southwestern Internal Medicine Conference: bone disease in kidney failure: diagnosis and management
Q71448542	Special procedures for assessing metabolic bone disease
Q42114322	Specific locations of Langerhans cell histiocytosis in the child, scapula and pubis: report of two cases
Q99556575	Spectrum of microarchitectural bone disease in inborn errors of metabolism: a cross-sectional, observational study
Q44441928	Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis
Q33795328	Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential
Q100312241	Sports and Metabolic Bone Disease
Q94504208	Spotted bone disease
Q69002892	Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up
Q34182834	Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Q49671693	Staged Placement of Growing Rods for Metabolic Bone Disease and Insufficient Bone Quality: A Report of Two Cases.
Q36626054	State of the art systematic review of bone disease in anorexia nervosa
Q90647199	State-of-the-art imaging for diagnosis of metastatic bone disease
Q88042244	Steroid withdrawal and bone disease after kidney transplantation
Q54301758	Steroid withdrawal and bone disease after kidney transplantation - Authors' reply.
Q34453635	Strategies to minimize bone disease in renal failure
Q86313355	Study of Infigratinib in Children With Achondroplasia
Q73464879	Study of the mechanism of bone disease in hypophosphatemic glycosuric osteomalacia
Q46297871	Successful high-dose calcium treatment of aluminum-induced metabolic bone disease in long-term home parenteral nutrition
Q56087771	Sunlight “D”ilemma: risk of skin cancer or bone disease and muscle weakness
Q72006186	Supplement to the studies on marble bone disease
Q89593742	Surgical Reconstruction of the Acetabulum and Pelvis in Metastatic Bone Disease
Q68740089	Surgical aspects of metastatic bone disease
Q46122319	Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
Q71053652	Symposium on bone disease
Q70656264	Symposium on metabolic bone disease
Q68586929	Systematic radiologic approach for the diagnosis of temporal bone disease
Q93129049	Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies
Q47346663	Systemic bone disease associated with low serum copper levels in preterm low-birth weight twin infants
Q52327963	Systemic bone disease developing in small premature infants
Q54328421	Systemic bone disease in bony thorax.
Q72040686	Systemic bone disease in patients with mandibular atrophy
Q93169812	Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease
Q81244052	Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease
Q82542124	Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma
Q103773812	Systems for local, sustained release of zoledronic acid as a potential treatment for metastatic bone disease
Q58327158	T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
Q94189407	THE PARATHYROID GLANDS AND METABOLIC BONE DISEASE
Q77189726	THE ROLE OF STRONTIUM 85 IN THE DETECTION OF BONE DISEASE
Q91279009	Take actions to bridge the gaps between China and other countries: in the aspect of markers of mineral bone disease from China Dialysis Outcomes and Practice Patterns Study phase 5
Q26752158	Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders
Q104515257	Targeted nanomedicines for the treatment of bone disease and regeneration
Q34779835	Targeting protein kinases for bone disease: discovery and development of Src inhibitors
Q40206938	Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival
Q44503132	Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma
Q29040838	Tc99m-Sestamibi Uptake in Osteitis Fibrosa Cystica Simulating Metastatic Bone Disease
Q73367550	Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease
Q90304167	Technical feasibility, radiation dosimetry and clinical use of 18F-sodium fluoride (NaF) in evaluation of metastatic bone disease in pediatric population
Q50051475	Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment
Q74640685	Temporal bone disease in pre-Columbian America
Q71717638	Temporal bone disease: a comparison between high resolution computed tomography and pluridirectional tomography
Q92358412	Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease
Q87057071	Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report
Q33607092	Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report
Q55422686	Tetany following removal of a parathyroid adenoma with bone disease; finally alleviated with calciferol.
Q37239790	Th17 and Treg cells in bone related diseases
Q38206984	Thalassemia bone disease: a 19-year longitudinal analysis.
Q58433652	Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures
Q31145774	The "functional muscle-bone unit": a two-step diagnostic algorithm in pediatric bone disease
Q87865604	The Analgesic Effect of Calcitonin in Active Paget's Disease of Bone and in Metastatic Bone Disease
Q83308425	The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone
Q84508308	The CARI guidelines. Nutritional interventions for the prevention of bone disease in kidney transplant recipients
Q57693953	The CT flare response of metastatic bone disease in prostate cancer
Q64658489	The Effect of Osteopathic Manual Therapy on Vascular Supply
Q39984257	The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients
Q45171748	The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients
Q36011988	The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease
Q94286315	The Nature and Etiology of Bone Disease in Kashmir. The Conservative Surgery of Long Bones. Necrosis of the Lower Jaw
Q35992044	The RANKL system and the development of tumor-induced bone disease: lessons from pre-clinical models
Q64102143	The RANKL-RANK Axis: A Bone to Thymus Round Trip
Q38955994	The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer
Q26783615	The Role of Hedgehog Signaling in Tumor Induced Bone Disease
Q38713514	The Second Most Common Bone Disease: A Review on Paget's Disease of Bone
Q58767450	The Treatment of Large Tuberculous Abscess Associated with Bone Disease by Evacuation and Injection with a Solution of Iodoform in Ether
Q39653200	The Treatment of Pagetʼs Bone Disease with Sodium Ethidronate
Q72846407	The ^85Sr Scintiscan in Bone Disease
Q78468406	The arteriographic picture of metastatic bone disease
Q44000652	The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption
Q35036814	The bone disease of preterm birth: a biomechanical perspective
Q70095854	The bone scan in patients with aluminium-associated bone disease
Q72914415	The cellular basis of metastatic bone disease in patients with lung cancer
Q37645485	The child with bone pain: malignancies and mimickers
Q28345283	The clinical impact of metabolic bone disease in coeliac disease
Q41668073	The clinical significance of adynamic bone disease in uremia.
Q42263129	The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B.
Q36416306	The continuous challenge of cardiovascular and bone and bone disease in uremic patients: clinical consequences of hyperphosphatemia and advanced therapeutic approaches
Q69848746	The development and in-vivo behavior of tin containing radiopharmaceuticals--II. Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease
Q67063550	The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease
Q91572017	The effect of meals on bone turnover - a systematic review with focus on diabetic bone disease
Q55068429	The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Q68807410	The effect of the dihydroxylated metabolites of vitamin D and dietary phosphate restriction on bone disease in uraemic rats
Q38960721	The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Q81266686	The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region
Q38163937	The effects of bortezomib on bone disease in patients with multiple myeloma
Q45059059	The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer
Q70271999	The efficacy of various treatment modalities on aluminium associated bone disease
Q79662377	The eleventh rib biopsy in the study of metabolic bone disease
Q37334601	The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
Q67438971	The evolution of bone disease in patients on RDT for 10 years or more
Q58327150	The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3
Q44593072	The heterogeneity of bone disease in cirrhosis: a multivariate analysis
Q53757094	The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Q34721536	The impact of renal bone disease on the quality of life of ESRD patients.
Q69878546	The importance of early treatment of renal bone disease in children
Q37645458	The incidental skeletal lesion: ignore or explore?
Q46282742	The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis
Q35611123	The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease
Q70247827	The influence of systemic bone disease on bone resorption following mandibular augmentation
Q71066459	The influence of the calcium/phosphorus ratio in the diet on human bone disease, the role of nutritive secondary hyperparathyroidism
Q37846524	The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder
Q67753110	The investigation and treatment of renal bone disease
Q54331302	The labyrinth of bone disease in thalassaemia: the search for Ariadne's thread continues.
Q37136086	The link between bone disease and cardiovascular complications in hemodialysis patients
Q24671153	The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins
Q57260202	The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins
Q69800626	The liver and metabolic bone disease
Q37411210	The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice
Q71888297	The marble bone disease of the adult (M. Albers-Schönberg, osteopetrosis). II. Biochemical studies
Q36633785	The measurement of pain from metastatic bone disease: capturing the patient's experience
Q37720657	The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression
Q67926511	The metabolic bone disease of primary sclerosing cholangitis
Q40928793	The mineral content of bone and the activity of alkaline bone phosphatase in renal bone disease treated with dialysis and after kidney transplantation
Q46130869	The morbidity of bone disease in thalassemia
Q46672297	The outcomes of a standardized approach to managing metabolic bone disease of prematurity
Q37136324	The pathogenesis of the bone disease of multiple myeloma.
Q34485148	The pathophysiology and management of renal bone disease in dialysis patients
Q35179718	The pathophysiology of bone disease in gastrointestinal disease
Q72094729	The pattern of bone disease in transfusion-dependent thalassemia major patients
Q67692688	The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure
Q96610742	The potential of bone disease for personal identification: a case of tuberculosis
Q91012010	The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice
Q42932963	The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats
Q74308647	The radiographic appearance of metastatic bone disease
Q75749405	The radiological diagnosis of bone disease
Q37877712	The relationship among proton pump inhibitors, bone disease and fracture
Q39858698	The relationship between disturbed metabolism of vitamin D and bone disease in chronic renal failure
Q70610965	The relative merits of thermoscanning and gamma scanning in the detection of metastatic bone disease
Q100962567	The rise of metastatic bone disease in Ireland
Q36290002	The role of 18F-NaF PET/CT in metastatic bone disease
Q77916949	The role of bisphosphonates for the treatment of bone disease in multiple myeloma
Q60673818	The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials
Q82943621	The role of bone biopsy in evaluating bone disease
Q73032307	The role of calcium and phosphorus in metabolic bone disease
Q59340101	The role of imaging in the skeletal involvement of mucopolysaccharidoses
Q73669842	The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: a preliminary report
Q81097048	The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease
Q35401594	The role of peripheral nerve fibers and their neurotransmitters in cartilage and bone physiology and pathophysiology
Q55344958	The role of postoperative radiation and coordination of care in patients with metastatic bone disease of the appendicular skeleton.
Q87885370	The role of renal bone disease in the production of transplant osteonecrosis
Q40464930	The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.
Q84410511	The role of the laboratory in investigation and management of bone disease
Q74586679	The role of the orthopaedic surgeon in metastatic disease of the appendicular skeleton. Working Party on Metastatic Bone Disease in Breast Cancer in the UK
Q36975213	The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer
Q81428925	The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma
Q79224441	The skull in hyperparathyroid bone disease
Q74464020	The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings
Q34522687	The spectrum of bone disease in Jordanian hemodialysis patients
Q70580279	The spectrum of bone disease in end-stage renal failure--an evolving disorder
Q68748504	The spectrum of metabolic bone disease in lymphoblastic leukemia
Q83665168	The spectrum of renal bone disease: introduction
Q40496318	The treatment of metabolic bone disease in patients on peritoneal dialysis
Q76052383	The treatment of tuberculous bone disease by surgical drainage combined with streptomycin
Q78881825	The tubular reabsorption of phosphate in the differential diagnosis of metabolic bone disease
Q67954978	The urinary excretion of the collagen degradation markers pyridinoline and deoxypyridinoline in an experimental rat model of alcoholic bone disease
Q40370055	The use of alfacalcidol in the prevention of bone disease in early renal failure
Q62544981	The use of laser spectroscopy to investigate bone disease in King Henry VIII's sailors
Q67014924	The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease
Q35550375	The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia
Q38286700	The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD).
Q37982124	The validity of biochemical markers in metabolic bone disease in preterm infants: a systematic review
Q70763873	The value of radioimmunoassay of parathyroid hormone in diagnosis of hyperparathyroidism, renal calculi, hypercalcaemia and metabolic bone disease
Q39502215	The zickel nail in the treatment of metastatic bone disease in the upper end of the femur
Q102218065	Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease
Q38001843	Therapeutic approaches to myeloma bone disease: an evolving story
Q36092153	Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
Q57172251	Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
Q35637476	Therapeutic interventions targeting the nitric oxide system: current and potential uses in obstetrics, bone disease and erectile dysfunction
Q90921518	Therapeutic targets in myeloma bone disease
Q90974759	Thermal ablation to relieve pain from metastatic bone disease: a systematic review
Q71527503	Thermography and panography in diagnosis of bone disease
Q95788323	Thermography as an aid in the diagnosis of tumours and detection of metastatic bone disease
Q69056694	Thermography in Bone Disease
Q92242661	They are not alone - Cell system and bone disease
Q41746957	Thirty years of bone disease in Geneva
Q101406551	Thirty-day Outcomes After Surgery for Metastatic Bone Disease of the Extremities: An Analysis of the NSQIP Database
Q91242920	Thirty-day Postoperative Complications After Surgery For Metastatic Long Bone Disease Are Associated With Higher Mortality at 1 Year
Q59335355	Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
Q99554541	Thrombospondins in bone remodeling and metastatic bone disease
Q72631878	Thyrotoxic bone disease in women: a potentially reversible disorder
Q67462130	Thyrotoxic osteodystrophy: a perplexing type of metabolic bone disease
Q53565333	Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Q72055512	Total body calcium by whole body neutron activation: new technique for study of bone disease
Q33932610	Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures
Q90495902	Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease
Q31155741	Transgenic models of metabolic bone disease: impact of estrogen receptor deficiency on skeletal metabolism
Q46631137	Transplantation: An end to bone disease after renal transplantation?
Q33881885	Transversal study on the prevalence of Metabolic Bone Disease (MBD) and Home Parenteral Nutrition (HPN) in Spain: data from NADYA group
Q84501495	Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study
Q38742231	Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223.
Q70808771	Treatment of Paget's bone disease with a bisphosphonate
Q70475447	Treatment of Paget's bone disease with the bisphosphonate APD
Q94204735	Treatment of Tuberculous Bone Disease
Q35207848	Treatment of adynamic bone disease in a haemodialysis patient with teriparatide
Q34465638	Treatment of adynamic bone disease with the complete replacement from calcium carbonate to sevelamer hydrochloride
Q80041469	Treatment of anticonvulsant drug-induced bone disease
Q34493365	Treatment of bone disease after jejunoileal bypass for obesity with oral 1 alpha-hydroxyvitamin D3.
Q41183271	Treatment of bone disease caused by gastrectomy
Q45171735	Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines
Q35930630	Treatment of bone disease in cystic fibrosis
Q67781747	Treatment of bone disease in patients on chronic hemodialysis with dihydrotachysterol
Q42769085	Treatment of bone disease with dihydrotachysterol in patients undergoing long-term hemodialysis
Q72360367	Treatment of deformity secondary to metabolic bone disease with the Ilizarov technique
Q46711944	Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation.
Q69875907	Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination
Q36067693	Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists
Q34567686	Treatment of metastatic bone disease in breast cancer: bisphosphonates
Q30868833	Treatment of multiple myeloma bone disease: experimental and clinical data.
Q66705111	Treatment of renal bone disease
Q66967977	Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses
Q41782302	Treatment of renal bone disease with 1-alpha hydroxycholecalciferol
Q85958046	Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study
Q69699127	Treponemal bone disease in an Ethiopian immigrant
Q44405118	Triazolopyrimidine (Trapidil), a Platelet-Derived Growth Factor Antagonist, Inhibits Parathyroid Bone Disease in an Animal Model for Chronic Hyperparathyroidism
Q83202594	Tumor bone disease
Q60923341	Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease
Q37771082	Tumor-host cell interactions in the bone disease of myeloma
Q36107833	Turner's syndrome presenting as metabolic bone disease
Q78706751	Two cases of fibrous bone disease of apparent maxillary origen
Q73325613	Two cases of pediatric bone disease (eosinophilic granuloma and Brodie's abscess) showing similar scintigraphic and radiographic findings
Q91566226	Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma
Q70899097	Unclassified Demineralising Bone Disease in an 8 Years Old Girl: Report of a Case
Q100528801	Understanding Bone Disease in Patients with Diabetic Kidney Disease: a Narrative Review
Q38975635	Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children
Q34547870	Unexplained Fractures: Child Abuse or Bone Disease? A Systematic Review
Q43880141	Unilateral exophthalmia caused by the sarcomatous degeneration of Paget's bone disease
Q43603212	Unmet needs in metastatic bone disease and its complications: is progress possible?
Q77148192	Unusual case of metabolic bone disease in a common marmoset (Callithrix jacchus)
Q37570903	Update on cystic fibrosis-related bone disease: a special focus on children
Q62071798	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease
Q33845933	Uremic bone disease: advances over the last 30 years
Q37042550	Uremic bone disease: current knowledge, controversial issues, and new horizons
Q67273045	Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease
Q72330066	Urinary hydroxyproline excretion in orthopedic disease, with special reference to systemic bone disease and bone tumor (secondary report)
Q71410166	Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease
Q80952780	Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease
Q77370300	Urolithiasis/calcinations in renal graft--a link with renal transplant bone disease treatment?
Q72785796	Use of Dichloromethylene Diphosphonate in Metastatic Bone Disease
Q40942406	Use of Massive Allografts to Manage Hydatid Bone Disease of the Femur.
Q91915639	Use of bone densitometry to assess bone disease in aluminum toxicity complicating parentral nutrition: A case report
Q80210417	Use of bone health protocol to identify and prevent bone disease in kidney and pancreas transplant recipients
Q70548409	Use of dichloromethylene diphosphonate in metastatic bone disease
Q82458264	Use of hormone replacement therapy for correction of high turnover bone disease in hypogonadal β-Thalassemia major patients presenting with osteoporosis: comparison with idiopathic premature ovarian failure
Q70980348	Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload
Q58753623	Using Mendelian Randomization to Decipher Mechanisms of Bone Disease
Q39419692	Utility of Plain Radiographs in Metabolic Bone Disease - A Case-Based Pictorial Review from a Tertiary Centre
Q80145429	VIth meeting on cancer-induced bone disease
Q86621454	Valvular calcifications in CKD: Mineral and bone disease or previous cardiovascular risk?
Q86621451	Valvular calcifications in chronic kidney disease: Mineral and bone disease or previous cardiovascular risk? Response
Q37804557	Vanishing Bone Disease: A Review
Q80646260	Vanishing bone disease
Q34047815	Vanishing bone disease (Gorham-Stout syndrome): A review of a rare entity
Q35120821	Vanishing bone disease in a five year old: report of a case and review of the literature
Q46903030	Vanishing bone disease involving the pelvis
Q37630623	Vanishing bone disease of chest wall and spine with kyphoscoliosis and neurological deficit: A case report and review of literature
Q38127284	Vanishing bone disease of the mandible - a case report
Q39167972	Vanishing bone disease of the orbital roof: now you see it, now you don't
Q53607555	Vanishing bone disease of the pelvis.
Q67417478	Vanishing bone disease: a case report
Q53728231	Vanishing bone disease: a manifestation of diabetic Charcot's neuropathic osteoarthropathy.
Q37416642	Vanishing bone disease: review and case reports
Q74106916	Variable bone mass recovery in hyperthyroid bone disease after radioiodine therapy in postmenopausal patients
Q80164218	Variant of adynamic bone disease in hemodialysis patients: fact or fiction?
Q92400368	Veterans Aging Cohort Study Index as a Marker of Bone Disease in HIV-Infected Patients
Q71239379	Vitamin A and hyperparathyroid bone disease in uremia
Q96228247	Vitamin C deficiency mimicking inflammatory bone disease of the hand
Q44328316	Vitamin D Deficiency and Bone Disease in Gastrointestinal Disorders
Q40519915	Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder
Q73067482	Vitamin D analogs: from renal bone disease to osteoporosis
Q24245248	Vitamin D analogues for the treatment and prevention of bone disease in chronic kidney disease
Q41736064	Vitamin D and analogues in renal bone disease and implications for osteoporosis.
Q43233968	Vitamin D and bone disease
Q37620414	Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD).
Q33815036	Vitamin D and human skeletal muscle
Q40243774	Vitamin D and metabolic bone disease: a clinicopathologic overview.
Q71793447	Vitamin D deficiency and bone disease in patients with Crohn's disease
Q72115783	Vitamin D deficiency and bone disease in patients with Crohn's disease
Q68515708	Vitamin D deficiency and hyperparathyroidism with severe bone disease
Q87439943	Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation
Q34436389	Vitamin D nutrition and bone disease in adults
Q92079552	Vitamin D status among preterm infants with cholestasis and metabolic bone disease
Q69727855	Vitamin D, desferrioxamine and aluminum-induced bone disease in uremic rats
Q77216392	Vitamin D3 withdrawal in hemodialysis patients with adynamic bone disease
Q93129498	WITHDRAWN: They are not alone - Cell System and Bone Disease
Q88431590	WITHDROWN: Osteonecrosis of the jaw in patients traited by denosumab for malignant bone disease: Descriptive study on 9 cases
Q87093875	WNT1 mutations responsible for rare forms of genetic bone disease
Q46564690	Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid
Q58057640	What community measurements can be used to predict bone disease in patients with COPD?
Q88152593	What does vanishing bone disease look like?
Q35630037	What is MRI bone oedema in rheumatoid arthritis and why does it matter?
Q69964340	What is your diagnosis? Multifocal lytic bone disease
Q71259508	When is vitamin D-responsive bone disease not osteomalacia?
Q36715848	Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
Q34488996	Who gets renal bone disease before beginning dialysis?
Q36842459	Whole-body imaging of the musculoskeletal system: the value of MR imaging
Q27028113	Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease
Q77814012	Widespread bone disease in acute myeloid leukaemia
Q40950656	Will bone disease still remain one of the most serious complications in dialysis patients?
Q36742501	Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Q41840832	Worsening of bone disease after curative surgery in primary hyperparathyroidism
Q67797393	X-rays in focus: bone disease in children
Q99554749	Your role in early diagnosis & Tx of metastatic bone disease
Q34320376	Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.
Q46720873	Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
Q44839660	Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: a novel molecular mechanism.
Q42721261	Zoledronic acid in metastatic bone disease: an audit based discussion
Q38170525	Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Q41687221	Zoledronic acid in the management of metastatic bone disease
Q44348524	Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Q35095225	Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis
Q79196678	[2 Cases of "scintillatio nivea" associated with cataracts of juvenile type. Paget's bone disease in the first, generalized choroid sclerosis in the other.]
Q70705003	[2d case of marble bone disease in a family]
Q95586506	[A case report of multiple spontaneous bone fractures in a patient with alcoholic liver disease and metabolic bone disease]
Q73060636	[A connatal bone disease with symptoms of an atypic eosinophilic granuloma]
Q73626772	[A new bone disease: osteopathia familiaris neuroendocrina]
Q90917362	[Advances and perspectives of the study on osteolytic bone disease of multiple myeloma]
Q73855063	[Adynamic bone disease and relative hypoparathyroidism in uremia]
Q72385284	[Adynamic bone disease in kidney failure. Role of aluminum]
Q80334058	[Adynamic bone disease]
Q73646487	[Adynamic bone disease]
Q95358119	[Adynamic bone disease]
Q84310190	[Adynamic bone disease]
Q54271932	[Aluminum associated bone disease in patients undergoing long-term hemodialysis].
Q72745064	[Aluminum-related bone disease in chronic hemodialysis patients]
Q69627615	[Aminoaciduria and aminoacidemia in a case of marble bone disease]
Q73589704	[Aminoaciduria in cystin thesaurismosis and marble bone disease]
Q77078175	[An unusual bone disease, not easily classified, in an infant]
Q51889734	[Animal models for bone and joint disease. Bone disease of osteoprotegerin deficient mouse].
Q64377579	[Application of gene therapy mediated by adenovirus vectors for bone trauma and bone disease]
Q95366130	[Applications and progress of Fourier transform infrared spectroscopic microimaging in bone disease research]
Q100695244	[Applied Value of Serum Bone Turnover Markers in Patients with Myeloma Bone Disease]
Q73511945	[Aspects of pseudo-tumoral bone disease]
Q69813481	[Bedside nursing. Nursing of a patient with marble bone disease with fracture of the left femoral neck]
Q45930347	[Black bone disease of the skull and facial bones].
Q82765959	[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in clinical trials for osteoporosis in Japan]
Q57219189	[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD]
Q82765967	[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Progress in X-ray analysis of bone]
Q74320322	[Bone changes, especially of the cranium, caused by marble bone disease]
Q75713267	[Bone disease and central regulatory disturbances.]
Q73667199	[Bone disease as an occupational disease in heavy industry]
Q104512563	[Bone disease as the first manifestation of systemic AL-amyloidosis]
Q71045891	[Bone disease associated with chronic renal failure]
Q73047273	[Bone disease due to hyperparathyroidism; extirpation of adenoma]
Q80056779	[Bone disease following renal transplantation]
Q53180363	[Bone disease in Gaucher's disease].
Q83044894	[Bone disease in multiple myeloma and its mechanism]
Q70715410	[Bone disease in multiple myeloma. Analysis of 253 controlled cases, with reappraisal of diagnostic criteria and current imaging techniques]
Q53634328	[Bone disease in multiple myeloma].
Q93680297	[Bone disease in patients undergoing chronic hemodialysis treatment and the role in its development of magnesium in drinking water used in the preparation of dialysis solution]
Q71261953	[Bone disease in patients with chronic renal insufficiency--on the problem of early diagnosis (author's transl)]
Q57141462	[Bone disease in primary biliary cirrhosis]
Q53093603	[Bone disease in the field of CKD-MBD].
Q53388747	[Bone disease with Pain. Colles' fracture].
Q81736371	[Bone disease with Pain. Non-traumatic osteonecrosis of the femoral head]
Q80142809	[Bone disease with Pain. Stress fracture]
Q80621587	[Bone disease with pain. Legg-Calvé-Perthes' disease (LCPD)]
Q81368392	[Bone disease with pain. Osteomyelitis in the long bone]
Q82178976	[Bone disease with pain. Tibial plateau fracture]
Q90920358	[Bone disease: its molecular mechanisms and bone metabolism]
Q83738222	[Bone fracture and the healing mechanisms. Metabolic bone disease and skeletal healing]
Q73541159	[Bone scintigraphy in metastatic bone disease]
Q71261956	[Calcitonin in the treatment of Paget's bone disease]
Q72808794	[Calcitonin treatment of metabolic bone disease induced by parenteral nutrition]
Q74205028	[Canine panosteitis--an idiopathic bone disease investigated in the light of a new hypothesis concerning pathogenesis. Part two: Biochemical aspects and investigations]
Q80414097	[Characteristic features of bone disease in disseminated carcinomatosis of bone marrow]
Q52865588	[Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers].
Q86561859	[Clinical guidelines for bone disease in primary biliary cirrhosis]
Q81408333	[Clinical relevance of biomarkers in cancer related bone disease]
Q95545778	[Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease]
Q95428749	[Complications and their management in multiple myeloma patients: bone disease, renal impairment and peripheral neuropathy]
Q71849890	[Congenital familial osteopetrosis (marble bone disease Albers-Schönberg). A contribution to the pathogenesis]
Q54349493	[Countermeasure for patients with bone disease due to hemodialysis].
Q79368139	[Critical analysis of pathophysiological, diagnostic and therapeutic aspects of metabolic bone disease in very low birth weight infants]
Q73696746	[Current research and findings in Paget's bone disease]
Q87971821	[Cytokines and myeloma bone disease]
Q78924197	[Deceptive radiological aspects of Recklinghausen's bone disease]
Q86478360	[Detection of serum DKK1 in multiple myeloma and myeloma bone disease]
Q79432507	[Diagnosis of bone disease based on needle biopsy]
Q69438304	[Diagnosis of uremia-induced bone disease using absorption measurement with a 125-I profile scanner]
Q76186138	[Differential diagnosis of the principal bone diseases. IV. Differential diagnosis of diffuse skeletal induration, especially marble bone disease and other osteoscleroses]
Q73115349	[Difficulties in the differential diagnosis of bone disease]
Q74488122	[Dyshormonal strain bone disease in young people]
Q87427011	[Effect of CCL3 on osteoblast in myeloma bone disease]
Q74406732	[Effect of bisphosphonate on myeloma bone disease]
Q72831384	[Effect of calcitriol, a vitamin D compound, in bone disease associated with distal renal tubular acidosis]
Q81540706	[Effect of concomitant therapy on adynamic bone disease]
Q84096600	[Effect of different regimens on bone disease of multiple myeloma]
Q72314824	[Effect of parathyroidectomy (PTX) on aluminum (Al) induced bone disease]
Q74134830	[Enthesiopathy and bone disease during the course of inflammatory spondylarthropathies. Diagnostic and physiopathologic importance]
Q81540699	[Erythropoietin remedy and adynamic bone disease]
Q74212635	[Familial Albers-Schönberg's marble bone disease with congenital spondyloysis of the fifth lumbar vertebra]
Q83232679	[Fibrous dysplasia and McCune-Albright syndrome: case-report and differential diagnose with Paget bone disease]
Q82348962	[Generalized bone disease in childhood]
Q83362433	[Generalized bone disease in childhood]
Q77142319	[Generalized hereditary bone disease in a nine-and-a-half year old Korean boy.]
Q83868549	[Gluteal mass in elderly subject with Paget's bone disease]
Q83460367	[Guidelines for treatment of myeloma bone disease]
Q72692827	[Histological classification of uremic bone disease and clinical significance of bone biopsy]
Q53470983	[Imaging techniques in the evaluation of metastatic bone disease]
Q71199503	[Indications of parathyroidectomy for bone disease associated with secondary hyperparathyroidism]
Q100695236	[Interaction between Stromal Cell-Derived Factor 1 Alpha and Dickkopf-1 Involves in Occurence of Myeloma Bone Disease]
Q84957225	[Introduction. CKD-MBD (Chronic kidney disease-Metabolic bone disease)]
Q68963665	[Investigation on the causes of bone disease in patients with renal disease]
Q72344453	[Langerhans cell granulomatosis with unifocal bone disease and asymptomatic pulmonary infiltration]
Q71065338	[Left spontaneous femoral fracture in primary hyperparathyroidism and postgastrectomy bone disease following a Billroth II stomach resection]
Q81090404	[Low PTH level and adynamic bone disease in dialysis patients]
Q84821261	[Management of bone disease in multiple myeloma]
Q86082894	[Management of bone disease in myeloma patients: zoledronic acid or denosumab?]
Q82715995	[Management of mineral and bone disease caused by chronic renal disease: what recommendations have contributed]
Q95577475	[Management of multiple myeloma-related bone disease]
Q73404334	[Marble bone disease (Albers-Schönberg disease) with remarks on its differential diagnosis]
Q68479326	[Marble bone disease in adults (Albers-Schönberg disease, osteopetrosis). 3. Electron microscopic studies of bones in osteopetrosis]
Q52982502	[Marble bone disease: The role of SPECT/CT hybrid imaging].
Q77617921	[Marble bone disease]
Q80988212	[Mechanisms for formation of myeloma bone disease]
Q89302409	[Mechanisms of myeloma-induced bone disease]
Q54505799	[Mechanisms of osteogenic inhibition in myeloma bone disease and its targeted therapy].
Q92842211	[Metabolic Bone Disease of Prematurity in Very Low Birthweight Infants: Retrospective Observational Study]
Q81090702	[Metabolic bone disease and bone quality]
Q71889703	[Metabolic bone disease in a female patient with gluten enteropathy]
Q95548158	[Metabolic bone disease in children with chronic gastrointestinal tract condition]
Q84494095	[Metabolic bone disease in liver cirrhosis: the influence of nutritional status]
Q87840401	[Metabolic bone disease osteomalacia]
Q69758532	[Metabolic bone disease: morphology and biochemistry of bones]
Q68937334	[Metabolic bone disease: osteogenic cells]
Q79249486	[Metabolic bone disease: something more than medication]
Q72712312	[Metabolic bone disease]
Q91247987	[Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: III. Bone Disease in Multiple Myeloma]
Q84672152	[Myeloma bone disease and RANKL signaling]
Q84560291	[Myeloma bone disease: pathogenetic mechanisms and targeted therapy]
Q52887243	[NF-κB signaling pathways and the future perspectives of bone disease therapy using selective inhibitors of NF-κB].
Q83144512	[New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease]
Q68503877	[New treatment of Paget's bone disease]
Q79210178	[Non-corticosteroid drug-induced metabolic bone disease]
Q83933097	[Novel markers in osteo-oncology: the tartrate resistant acid phosphatase in myeloma bone disease]
Q69797298	[Nuclear anomalies in osteoclasts in Paget's bone disease]
Q80261800	[Nutrition-related bone disease]
Q52319342	[Osteolathyrism: morphometrical, histochemical, and microradiographical investigations on an experimental bone disease (author's transl)]
Q71503656	[Osteomesopycnosis. A new autosomal dominant osteosclerosing bone disease (author's transl)]
Q81540686	[Osteoprotegerin and adynamic bone disease]
Q73599374	[Osteosarcoma manifesting as Paget's bone disease]
Q74022171	[Paget's bone disease in gout]
Q53901184	[Paget's bone disease: a rare cause of leg ulcers]
Q78808528	[Paget's bone disease: medicoleoal considerations on the subject of disability in the legal sense.]
Q73899550	[Paget's bone disease]
Q77439844	[Paget's bone disease]
Q71983095	[Parapsoriasis and Paget's bone disease]
Q81540664	[Pathogenesis of adynamic bone disease]
Q74425386	[Pathological anatomy of generalized bone disease especially of osteoporosis, osteomalacia and generalized fibrous osteodystrophy as expression of metabolic disorders in bone tissue]
Q81539434	[Pathophysiology and clinical features of adynamic bone disease]
Q68899355	[Prevalence of histological types of bone disease in a hemodialysis center limiting the oral intake of aluminum hydroxide]
Q86773652	[Prevention and treatment of multiple myeloma bone disease]
Q53696928	[Preventive management of bone disease in advanced prostate cancer.]
Q71929196	[Pseudosarcomatous osteolysis of the femur in a patient with Paget's bone disease treated with long-term etidronate disodium: apropos of a new case]
Q68661092	[Radiological measurement of compact bone thickness in children with generalized bone disease]
Q81538796	[Renal bone disease and osteoprotegerin]
Q73786314	[Renal bone disease]
Q74622200	[Renal osteodystrophy--more than a mere bone disease]
Q54111742	[Rheumatologic manifestations of sarcoidosis].
Q74010507	[Risk factors of adynamic bone disease in children with end-stage renal failure: personal experience]
Q81540703	[Role of advanced glycation endproducts in adynamic bone disease]
Q73973989	[Role of computerized tomography in the diagnosis of bone disease in multiple myeloma]
Q69758774	[Scintigraphy presentation. Bone scintigraphy of marble bone disease]
Q73544281	[Sclerotic bone disease of congenital or genetic origin. Atlas of Radiological Clinic Vol. 27]
Q74442875	[Screening for bone disease risk with clinical factors in women after physiologic menopause]
Q93380915	[Secondary osteoporosis. Bone disease in liver cirrhosis.]
Q68784766	[Serum alkaline phosphatases as an indicator of liver and bone disease in chronically dialyzed patients]
Q84103183	[Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease]
Q73151724	[Statistical study of 365 patients observed in a rheumatology and bone disease clinic]
Q70407668	[Studies on bone disease and serum A1-P isozymes of patient on long term regular hemodialisis (author's transl)]
Q73578187	[Studies on metabolic processes in Albers-Schönberg marble bone disease]
Q71109174	[Surgical optic nerve decompression in marble bone disease (Albers-Schönberg disease)]
Q54671103	[Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
Q86041149	[The bone turnover markers of myeloma bone disease]
Q68418501	[The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease]
Q70545668	[The diagnostic value of the alveolar lamina dura in generalised bone disease (author's transl)]
Q74765105	[The hip in Paget's bone disease]
Q97560714	[The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease]
Q81540673	[The pathophysiology of adynamic bone disease]
Q74728236	[The relationship between bone mineral density and secondary hyperparathyroidism bone disease]
Q67999684	[The roentgenologic manifestations of dialysis bone disease (report of 53 cases)]
Q52986694	[The value of chest computerized tomography in evaluation of bone disease and clinical prognosis of multiple myeloma].
Q81539855	[Therapeutic vaccination approach against pathological bone disease]
Q72057998	[Tooth and jaw findings in infantile marble bone disease]
Q70741405	[Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications]
Q73072386	[Unusual diffuse bone disease]
Q76048486	[Unusual location of Looser's transformation zones in alimentary bone disease]
Q87339738	[Utility of bone turnover markers in metabolic bone disease detection in patients with phenylketonuria]
Q67866883	[Vitamin D and bone disease due to dialysis]
Q49573729	[[GUIDELINES FOR THE PREVENTION, MONITORING AND THERAPY OF CHRONIC KIDNEY DISEASE-METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE].]
Q72132587	beta 2-Microglobulin in Paget's bone disease
Q26823362	¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review

P7033	Australian Educational Vocabulary ID	scot/11413
P2581	BabelNet ID	00353184n
		00353184n
P6706	De Agostini ID	osteopatìa
P699	Disease Ontology ID	DOID:0080001
P1417	Encyclopædia Britannica Online ID	science/bone-disease
P2888	exact match	http://identifiers.org/doid/DOID:0080001
		http://purl.obolibrary.org/obo/DOID_0080001
P11956	Experimental Factor Ontology ID	0004260
P4229	ICD-10-CM	M89.9
P493	ICD-9 ID	730
		733
P1692	ICD-9-CM	733.99
		731.8
P8408	KBpedia ID	DiseaseAfflictingPart-Bone-BodyPart
P486	MeSH descriptor ID	D001847
P672	MeSH tree code	C05.116
P6366	Microsoft Academic ID	2776169692
P5270	Mondo ID	MONDO_0005381
P1368	National Library of Latvia ID	000110975
P691	NL CR AUT ID	ph136970
		ph870500
P10283	OpenAlex ID	C2776169692
		C2910508087
P4527	UK Parliament thesaurus ID	8730
P2892	UMLS CUI	C0005940
P8370	UNBIS Thesaurus ID	1000658
P2347	YSO ID	10782

P689	afflicts	bone	Q265868
P927	anatomical location	bone	Q265868
P1889	different from	osteopathy	Q325253
P2176	drug or therapy used for treatment	ibandronic acid	Q166825
		denosumab	Q408283
		teriparatide	Q411781
		deferoxamine	Q419618
		alendronic acid	Q420057
		raloxifene	Q425223
		zoledronic acid monohydrate	Q28852343
P1995	health specialty	rheumatology	Q327657
P5008	on focus list of Wikimedia project	WikiProject Medicine	Q4099686
P910	topic's main category	Category:Osteopathies	Q7215422

Q124640990	Alpa Desai
Q120600149	Andreas Maassen
Q112514975	Angelika Strunk
Q120601678	Arndt Fengler
Q112514536	Bhavesh T. Joshi
Q124623581	Claudia Weingand
Q112512422	Claus-Peter Adler
Q42594902	César Fernández-de-las-Peñas
Q120603583	Daniel Dierlmeier
Q112514287	Daniel Monconduit
Q29054748	Edwards A. Park
Q98618966	Francesco Bertoldo
Q57335101	Françoise Mathieu
Q51094785	Gary Cook
Q91211787	Giorgio Perino
Q115957979	Jana Holubová
Q112343977	Joeri Calsius
Q112564971	Jérôme Helsmoortel
Q119807859	Jörg Halfmann
Q112534850	Leonard O. Langer
Q112547485	Paolo Tozzi
Q112520285	Peter Przekop
Q112564973	Peter Wührl
Q112555211	S. Miles Standish
Q112509463	Sascha Seifert
Q90418657	Slobodan Vukicevic
Q120615983	Thomas Attlee
Q112564972	Thomas Hirth
Q112492101	Wim Hermanns
Q124832329	Yash Chavda
Q15064994	Татьяна Павловна Виноградова

Q624398	Blount's disease
Q62736	osteoarthritis
Q3266880	skeletal fluorosis

Q420057	alendronic acid
Q419618	deferoxamine
Q408283	denosumab
Q166825	ibandronic acid
Q425223	raloxifene
Q411781	teriparatide
Q28852343	zoledronic acid monohydrate

bone disease

medical condition which affects the bone

Reverse relations

The articles in Wikimedia projects and languages

Q55044913	Coxa Magna
Q5376307	Endocrine bone disease
Q1538277	Gorham's disease
Q632228	Hajdu-Cheney syndrome
Q48989142	Kenny-Caffey syndrome
Q6839441	Microdamage in bone
Q55749013	Osteitis condensans ilii
Q30314345	Osteolytic lesion
Q7168683	Periosteal reaction
Q7284803	Raine syndrome
Q110917535	abnormality of the metaphysis
Q708176	arthropathy
Q682798	bejel
Q18553654	bone benign neoplasm
Q18554919	bone cancer
Q5055163	bone cavitation
Q21109694	bone changes
Q826918	bone cyst
Q18553737	bone development disease
Q25339838	bone erosion
Q68833	bone fracture
Q1178507	bone inflammation disease
Q115571740	bone lesion
Q18556569	bone marrow disease
Q18553736	bone remodeling disease
Q18553740	bone structure disease
Q1076086	chondromalacia patellae
Q2165663	chronic granulomatous disease
Q167794	coccydynia
Q5189052	crouzonodermoskeletal syndrome
Q246046	cystic echinococcosis
Q2718677	du Pan syndrome
Q5334289	ectopic calcification
Q55783316	expansile bone lesions
Q1388855	fibrocartilage callus
Q5747886	heterotopic ossification
Q6029216	infectious bone disease
Q26695332	ischemic bone disease
Q25036443	malunion
Q6822340	metabolic bone disease
Q55789746	neoplasm of femur
Q18558098	orbital disease
Q6153637	osteoarticular tuberculosis
Q1367706	osteopenia
Q247096	paracoccidioidomycosis
Q1480377	periostitis
Q55788795	rare bone disease
Q3266880	skeletal fluorosis
Q55790744	skull disorder
Q54932080	slipped epiphysis
Q7577457	spinal disease
Q2165411	spondylitis
Q2046113	visceral leishmaniasis
Q76973	yaws
Q6007402	ostéose

Q110674945	Jean Derry	medical condition	P1050
Q325253	osteopathy	different from	P1889
Q7215422	Category:Osteopathies	category's main topic	P301
uri / http://www.wikidata.org/entity/L667011-S1	L667011-S1	item for this sense	P5137
Q3480107	bone pain	has cause	P828
Q7214863	Category:Deaths from skeletal disease	category combines topics	P971

Arabic (ar / Q13955)	مرض عظمي	wikipedia
az	Sümük xəstəliyi	wikipedia
	Bone disease	wikipedia
gl	Doenza ósea	wikipedia
Serbo-Croatian (sh / Q9301)	Bolest kostiju	wikipedia
	Bolest kostiju	wikipedia
	Bensjukdomar	wikipedia
ta	எலும்பு நோய்	wikipedia

Q18345025	Lance Carter
Q6499765	Laurel Burch